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ABSTRACT
Biphenyl 2-hydroxyIation was rapidly activated in rat 
liver microsomes by addition of glucocorticoids or «.naphtho- 
flavone whereas 3- and 4-hydroxylation were unaffected. 
Betamethasone was the most effective activator.
Betamethasone and ocnaphthoflavone also activated benzo(a)- 
pyrene 3-hydroxylation and antipyrine 4-hydroxylation. The 
inter-relationship between these activating agents and the 
susceptible enzyme activities has been investigated, showing 
many similarities and some differences.
Activation of biphenyl 2-hydroxylation by betamethasone 
appeared to be unrelated to activation of aromatic amines and 
UDP-glucuronyltransferases.
Activation was not affected by pretreatment of rats with 
inducing agents but was abolished by addition of the inhibitor 
me ty rap one to microsomal incubations.
A marked and most unusual sex difference in activation 
was found. Activation did not occur in liver micro somes from 
adult female rats whereas activation in microsomes from immature 
female rats resembled that from immature male rats. Activation 
in extrahepatic tissues has also been investigated.
An attempt has been made to elucidate the mechanism of 
activation. There appears to be a direct effect on a cytochrome 
P-450 dependent enzyme(s), not mediated via the surrounding 
membrane or the associated reductases. It is suggested that 
multiple enzymes may be involved in biphenyl 2-hydroxylation 
and benzo (a)pyrene 3-hydroxylation and that betamethasone and 
ocnaphthoflavone may aliosterically activate one or more of 
these forms.
Activation also occurred in human liver microsomes, in 
isolated rat hepatocytes and in liver microsomes following
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pretreatment of rats with betamethasone. An important 
physiological role is proposed for activation by glucocorticoids 
allowing rapid regulation of enzyme activities before the 
longer term control, induction, can occur.
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CHAPTER ONE
INTRODUCTION
1.1 GENERAL INTRODUCTION
The widespread use of an increasing number of chemicals 
such as pharmaceuticals, agricultural chemicals and food 
additives imposes a considerable burden upon man and his 
environment. The intensity and duration of action of many 
drugs are largely determined by the rate at which they are 
absorbed, metabolised and excreted from the body. Similarly, 
many other foreign compounds (xenobiotics) that are absorbed 
by the body are lipophilic entities and must be metabolised to 
water soluble compounds before they can be excreted by the 
kidneys into the urine, or by the liver into the bile.
Xenobiotic metabolism occurs mainly in the liver but has 
also been observed in virtually every other tissue that has 
been studied. Metabolism can be classified into two phases, 
phase I (bio transformation or functional i sat ion) and phase II 
(conjugation) (Williams, 1959). Phase I reactions included 
oxidation, reduction and hydrolysis which introduce (or expose) 
electronegative groups such as hydroxyls, amines, oxides and 
carboxylic acids into the molecule. In phase II, the phase I 
metabolite, or occasionally the parent xenobiotic, is conjugated 
with glucuronic acid, sulphate, glutathione, methyl and acetyl 
groups and amino acids. Other, less common pathways have been 
reviewed by Jenner and Testa (1978).
Many phase I reactions are catalysed by the cytochrome 
P-450 dependent monooxygenases. Cytochrome P-450 is the 
collective name for a group of haemoproteins which bind in the 
reduced foirm to carbon monoxide to give a complex that exhibits 
maximum absorbance at approximately 450nm (Omura and Sato, 1964). 
These enzymes catalyse such diverse reactions as the hydroxylation 
of unsaturated and saturated hydrocarbon groups, oxidative 
cleavage of alkyl-aryl ethers, sulphoxidation of thio ethers, 
epoxidation of unsaturated hydrocarbon groups and N-hydroxylation 
of aryl amines and acetylated aryl amines.
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Xenobiotic metabolism by monooxygenases varies widely 
among animal species, strains and individuals (Chhabra ^  al, 
1974; Davies _et 1969). In vertebrates these enzymes are 
located particularly in the endoplasmic reticulum of liver cells 
and can be isolated by cellular subfractionation in the form 
of fragments known as microsomes. Lesser amounts are found in 
many extrahepatic tissues including intestine, skin, kidney, 
spleen, brain, lymph nodes, salivary glands, prostate, pancreas 
and the steroidogenic tissues (Connelly and Bridges, 1980).
The endoplasmic reticulum and mitochondria of the adrenal 
cortex also contain certain forms of cytochrome P-450 which 
are involved predominantly in hydroxylation of steroids rather 
than xenobiotics. Mono oxygénas es have also been found in 
invertebrates, marine organisms^ bacteria and yeasts (Blumberg, 
1978).
Monooxygénases metabolise a vast range of xenobiotics 
(Blumberg, 1978) and also endogenous compounds (Brenner, 1977). 
Many excellent reviews have been written of the cytochrome P-450 
complex (Blumberg, 1978; Estabrook ^  1973; Ullrich, 1977).
Basically the complex consists of cytochrome P-450, a NADPH- 
dependent flavoprotein and phospholipid. The reactions involved 
in mono oxygénât ion are summarised in Fig. 1.1 (Nebert and 
Jensen, 1979).
The initial step (l) is formation of the oxidised enzyme- 
substrate complex. The sequential uptake of two electrons then 
occurs as indicated (2). The first electron is donated by the 
flavoprotein NADPH-cytochrome c (P-450) reductase to form the 
ferrous haemoprotein. It has been suggested that this is the 
rate-limiting step in the sequence (Davies at 1969; Miwa
et alt 1978) but the evidence is not conclusive (see review 
by Holtzman, 1979). The second electron may be donated either 
via NADPH-cytochrome P-450 reductase or via cytochrome b^ which 
may be reduced by either NADPH or NADH (Hildebrandt and 
Estabrook, 1970). Addition of the second electron may be
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Fig. 1.1 Proposed scheme for the mechanism of catalysis by 
cytochrome P-450 (Nebert and Jensen, 1979).
R-OH R-H
P-450 (FeP^
(1)(6)
(R-H) P-450 (Fe)®"^(R-H) P-450(Fe-0)^'^
HOH
(2)(5)
HOOH
(R-H) P- 450 (Fe-HOOH)®"^ ;-H) P-450 (Fe)
(3)
(R-H) P-450 (Fe-bg)2H
-  5 -
subsequent to the formation of the active oxygen species (step 
(3) in the figure). The fully reduced oxygen is then pictured 
as undergoing protonation to form HO^ (4) followed by elimination 
of water and formation of an Fe-0 complex (5). Insertion of 
the oxygen atom into a favourably positioned C-H bond of the 
bound substrate yields the hydroxylated product with regeneration 
of oxidised cytochrome P-450 (6). This scheme also illustrates 
the mechanism by which peroxides may support substrate hydroxyl­
ation in the absence of oxygen and NADPH.
In the case of oxidised cytochrome P-450, the fifth 
coordination position is likely to be occupied by the S-group 
of a cysteinyl residue. In the absence of substrate there is 
also a sixth ligand of unknown structure present. This six- 
coordinated oxidised cytochrome P-450 has a characteristic 
low spin electronic paramagnetic resonance (EPR) signal which 
is converted to high spin after addition of substrates such 
as biphenyl, hexobarbital and ethylmorphine which exhibit 
type I binding spectra (A max 385-390nm, min 418-427nm).
Formation of the enzyme-substrate complex probably results 
in removal of the sixth ligand but the substrate cannot interact 
at this position unless it contains heteroatoms such as nitrogen, 
sulphur, phosphorus or oxygen. Thus substrates like aniline 
and imidazole form six-coordinated, low spin complexes which 
exhibit type II binding spectra (^min 390-405nm, 7^ max 425-435nm). 
Interaction of type II substrates with the iron of cytochrome 
P-450 prevents the formation of the high spin enzyme-type I 
substrate complex and therefore inhibits cytochrome P-450 and 
monooxygenase activity (Ullrich, 1977).
Another binding spectrum used to characterise cytochrome 
P-450 is that caused by reaction of ethyl isocyanide with the 
reduced cytochrome, which has maxima at 427 and 455nm that show 
a pH dependent variation in their relative sizes (Imai and 
Sato, 1967).
—  6 —
Metabolism is not always a detoxication process. If the 
initial oxidation product is an epoxide with a relatively high 
chemical stability it may dissociate from the cytochrome at 
this point. Such epoxides can be further metabolised to diols 
by epoxide hydrase or may undergo conjugation with glutathione 
leading to detoxication in both cases. Alternatively epoxides 
may bind to cellular macromolecules, which may cause toxicity 
(Blumberg, 1978; Wright, 1980). This is thought to be the route 
involved in the activation of many of the carcinogenic poly cyclic 
hydrocarbons (Sims ^  1974; de Pierre and Ernster, 1978),
aflatoxins (Campbell and Hayes, 1976) and many other carcinogenic 
and toxic chemicals. Metabolism of some drugs may produce 
pharmacologically active entities. An example of this is 
codeine which owes some of its analgesic activity to its 
metabolite, morphine (Welch, 1979).
Thus metabolism is arguably the most important factor 
involved in influencing the pharmacological activity or toxicity 
of a xenobiotic. It is therefore necessary to study the factors 
that can affect the activity of drug metabolising enzymes in 
order to obtain greater understanding of pharmacological and 
toxicological responses in different species and individuals.
The activities of drug metabolising enzymes may be altered 
in many ways. These may be direct or indirect effects via 
changes in the rates of enzyme synthesis or degradation. Enzyme 
activity may be affected directly by a compound binding to it 
either at the active site or at an allosteric site. The 
environment of the enzyme may be altered, particularly in the 
endoplasmic reticulum where phospholipid is of great structural 
importance. Cytochrome P-450 dependent mono oxygénas e activities 
may also be modulated by effects on the reductases. The aim of 
this thesis is to investigate activation of cytochrome P-450 
dependent mono oxygénas es, i.e. a rapid enhancement of enzyme 
activity, therefore unless particularly relevant, only factors 
affecting these enzymes will be reviewed here.
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1.2 ENVIRONMENTAL FACTORS AFFECTING MONOOXYGENASE ACTIVITY
The environment of a patient or experimental animal 
prior to, during, or after drug administration can have a 
significant impact on the effects of the drug. The effects of 
diet on drug metabolism have been reviewed extensively (Campbell 
and Hayes, 1974; Miller, 1976). Monooxygénase activity may be 
altered by the relative proportions of nutrients in the diet 
(Kato ^  al, 1968; Marshall and McLean, 1969; Kato, 1977), or 
by excess or deficiency of vitamins and trace minerals (Dingell 
et al, 1966; Becking, 1972; Becking, 1973; Carpenter and Howard, 
1974; Wade ^  al, 1975; Rikans et al, 1978).
The effects of the physical and chemical environment on 
drug metabolism have been reviewed by Sanvordeker and Lambert 
(1974). These factors include light, temperature, altitude 
and oxygen tension. Of these, light is probably of greatest 
importance here. Circadian rhythms of rat hepatic cytochrome 
P-450 related enzyme activities have been found with maxima 
in the early morning and minima in the afternoon (Nair and 
Casper, 1969; Tredger and Chhabra, 1977). Plasma corticosterone 
levels in the male rat follow a rhythm that is the inverse of 
that shown by hepatic drug metabolising enzyme activity 
(Radzialowski and Bousquet, 1968). This may be an indication 
that circadian rhythms are controlled by the hormones of the 
adrenal cortex. However, steroid metabolising enzyme activities 
are subject to similar rhythms to those of drug metabolism 
(Graef and Golf, 1979) and it cannot be stated whether the rhythms 
control the plasma corticosterone levels or vice versa. If 
corticosteroids are involved in regulation of drug metabolism 
they may in part cause the altered metabolism found in animals 
that are stressed by other environmental stimuli.
Drug metabolising activity may also be altered by various 
disease states as reviewed by Kato (1977) and is subject to
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species, developmental, sex and tissue differences which will 
be reviewed in Chapter 4.
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1.3 INHIBITION OF MONOOXYGENASE ACTIVITY
As the type I and type II binding spectra represent binding 
to different sites of cytochrome P-450, it might be expected 
that compounds exhibiting similar binding spectra would competi­
tively inhibit each other’s metabolism, but that compounds 
exhibiting different binding spectra would not. In some instances 
especially with type I substrates, this is correct. For example, 
the N-déméthylation of ethylmorphine is competitively inhibited 
by a variety of other type I substrates including hexobarbitone, 
chlorpromazine and SKF 525A ( 2- diethylamino ethyl- 2,2- diphenyl- 
valerate) (Gillette, 1971). However, other studies have revealed 
no consistent mechanism for the inhibition of mono oxygénas es.
Metyrapone (2-methyl-1,2-bis-(3-pyridyl)-1-propanone) is a 
type II compound, but contrary to expectations, exerts a greater 
inhibitory effect on type I compounds such as hexabarbitone and 
aminopyrine than on type II compounds. Indeed, low concentrations 
of metyrapone enhance hydroxylation of acetanilide (see section 
1.5.1) and much higher concentrations of metyrapone are necessary 
for inhibition to be observed (Leibman, 1969). It is possible 
therefore that metyrapone interacts with different substrate 
binding sites in different ways, or that it reacts at a single 
site in such a way as to cause different effects on different 
sites of substrate interaction (Leibman, 1969).
, The mechanism of inhibition may vary not only with type II 
inhibitor and type I substrate but also with the animal species. 
Inhibition of aminopyrine N-déméthylation by nicotinamide is 
competitive with rat liver microsomes but mixed with mouse liver 
microsomes (Sasame and Gillette, 1970)( Nicotinamide and 
SKF 26754-A ( 2-amino ethyl - 2,2 - dipheny Ival erate) produce biphasic 
inhibition of ethylmorphine N-déméthylation in mouse liver 
microsomes. At low inhibitor concentrations inhibition is 
noncompetitive whereas at higher concentrations inhibition is
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both competitive and noncompetitive (Sasame and Gillette, 1970) 
Type II compounds have been shown to depress reductase o.ctivity_ 
(Gigon ^  1969). They may also alter the affinity of
cytochrome P-450 for a type I substrate. These two effects, 
occuring by different mechanisms, may account for the mixed 
inhibitory effects of type II compounds on the metabolism of 
type I compounds (Gillette, 1971).
The inhibition effects reported above have been studied 
in vitro. Many inhibitors are also effective 5^ vivo provided 
that the absorption and distribution of the inhibitor favour 
its accumulation in the liver, that it is not highly toxic and 
that it is metabolised and excreted more slowly than the 
substrate (Anders, 1971).
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1.4 INDUCTION OF MONOOXYGENASE ACTIVITY
Several hundred compounds are known to stimulate drug 
metabolism by inducing liver microsomal enzymes and th^ subject 
has been extensively reviewed (Conney, 1967; Kuntzman, 1969; 
Remmer, 1972; Bresnick, 1978; Snyder and Remmer, 1979). Examples 
of inducing agents are to be found in virtually all classes 
of chemical in man’s environment including drugs, agrochemicals, 
environmental contaminants and naturally occurring compounds 
in food (Conney and Burns, 1972; Conney ^  1977).
Induction of monooxygenase activity involves increased 
synthesis of enzyme proteins which may be stimulated by a 
deficiency of enzyme activity due to a prolonged occupation of 
the active site of the enzyme by an excess of the lipid soluble 
substrate. Inducers are generally xenobiotics which are slowly 
metabolised substrates (Parke, 1975). For this reason inducers 
may also cause inhibition of the enzymes vitro or in the 
short term vivo before ^  novo protein synthesis can occur.
Inducing agents can be classified in several groups but 
the barbiturates and the poly cyclic aromatic hydrocarbons have 
been most extensively studied. The barbiturates, of which 
phenobarbitone shows the greatest inductive effect, induce the 
activity of almost all cytochrome P-450 mediated reactions, 
including the metabolism of ethylmorphine, hexobarbi tone, 
aminopyrine, acetanilide, benzo(a)pyrene and biphenyl. Pheno­
barbitone treatment causes increases in liver cytochrome P-450 
content, cytochrome P-450 reductase activity and after a 
considerable delay, in cytochrome b^ content (Remmer, 1972).
More recently de Barros et ^  (1978) reported that liver 
microsomal NADH-cytochrome b^ reductase activity is also increased
Phenobarbitone causes a maximum stimulation (several fold) 
of liver microsomal cytochrome P-450 after daily administration 
for three days. The characteristics of this cytochrome appear
-  12 -
similar to those of the cytochrome from livers of untreated 
animals by the following criteria:
(i) the complex of the reduced cytochrome with CO exhibits a 
maximum absorbance at 450nm (Sladek and Mannering, 1966),
(ii) the two absorbance maxima of the ethyl iso cyanide binding 
spectrum are increased by equal proportions and the equilibrium 
pH is the same as in controls (Sladek and Mannering, 1966),
(iii) the susceptibility of enzyme activities to the inhibitors 
SKF 525A and metyrapone is similar (Anders and Manner ing, 1966: 
Leibman, 1969).
The kinetics of monooxygénase activity also suggest a similarity 
between control and phenobarbitone pretreated rat liver microsomes 
Although the Vmax was increased, the apparent Km for the 
hydroxylation of benzo(a)pyrene and other substrates did not 
change when rats were treated with phenobarbitone (Alvares ^  al, 
1968) o However, Lu al (1973) demonstrated that purified 
liver cytochrome P-450 from phenobarbitone treated rats exhibits 
different substrate specificities from that of untreated rats. 
Antibody studies by Conney (personal communication) have 
provided further evidence for phenobarbitone induction of a 
novel form of cytochrome P-450.
Phenobarbitone not only stimulates drug metabolism activity 
in liver microsomes but also has a marked anabolic effect on 
liver, resulting in a 20-40% increase in microsomal protein 
per gram of liver and in total liver weight (Remmer and Merker, 
1963). Ultrastruetural studies have revealed that there is a 
marked proliferation of the smooth endoplasmic reticulum in 
the liver parenchymal cells after two to three injections of 
phenobarbitone, followed by an increase in rough endoplasmic 
reticulum after further injections (Orrenius 1965).
These workers further observed that an increased rate of micro soma 
phospholipid synthesis was the earliest detectable effect of 
phenobarbitone treatment, occurring as quickly as 3h after
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administration. As with other manifestations of enzyme induction, 
this increase was reduced by simultaneous administration of a 
protein synthesis inhibitor such as actinomycin D or puromycin 
with phenobarbitone.
Phospholipid synthesis is only increased in the early 
stages of induction and subsequently followed by a decrease in 
the turnover rate (Ishidate ^  al, 1978). Similarly, Jick and 
Shuster (1966) suggested that the increase in NADPH-cytochrome c 
reductase levels were due to both increased rate of synthesis 
and decreased rate of degradation. Thus it appears that the 
increased metabolism of many substrates following phenobarbitone 
administration may be due to the combined effects of increased 
levels of cytochrome P-450 and associated reductases, of total 
liver protein and of the phospholipids essential for the integrity 
of microsomal membranes.
In contrast, the administration of 3-me thy 1 cho lanthr ene 
(3MC) or benzo (a)pyr ene (typical poly eye lie aromatic hydrocarbon 
inducing agents) induces relatively few pathways. It enhances 
the metabolism of acetanilide and benzo(a)pyrene but not that 
of ethylmorphine, hexobarbital and aminopyrine. In animals 
receiving doses of phenobarbitone that cause maximal induction, 
the administration of benzo(a)pyrene causes a further stimulation 
of acetanilide hydroxylation, suggesting that these inducers 
exert their effects by different mechanisms (Gillette, 1971).
3MC treatment causes an apparent increase in liver cytochrome 
P-450 content but has no significant effect on cytochrome P-450 
reductase activity or liver weight and microsomal protein 
(Ishidate ^  1978). 3MC treatment results in a shift in
the peak of the CO-binding spectrum of rat liver microsomal 
cytochrome P-450 from 450nm to 448nm (Kuntzman et 1968).
Also the ratio of the two peaks of the ethylisocyanide binding 
spectrum and the equilibrium pH are altered (Sladek and Manner ing, 
1966). Liver microsomal enzymes from polycyclic hydrocarbon
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treated rats show different inhibitor susceptibility to those 
of control and phenobarbitone treated rats, oùNaphthoflavone 
(ANF) inhibits benzo(a)pyrene hydroxylation in liver microsomes 
from 3MC treated but not control or phenobarbitone treated rats 
(Wiebel 1971)© Treatment with 3MC has also been shown to
change the apparent Km as well as the Vmax of benzo (a)pyrene 
hydroxylation suggesting that the 3MC induced cytochrome has a 
greater affinity for the substrate (Alvares £t 1968). Using 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE), Alvares and Siekevitz (1973) associated three 
different molecular weight bands of cytochrome P-450 apoprotein 
Two of these bands were differentially increased by induction 
with 3MC or phenobarbitone. More recently Guengerich (1977) 
reported the chromatographic resolution of rat liver cytochrome 
P-450 into four fractions.
The above evidence suggests that the cytochrome induced by 
polycyclic hydrocarbons is different to that found in control 
and phenobarbitone treated animals. Hildebrandt ^  al (1968) 
reported that the forms of cytochrome P-450 with CO-binding 
spectra at 450nm and 448nm have very different extinction 
coefficients. Thus calculations using the same extinction 
coefficient for control and 3MC induced cytochrome P-450 may give 
rise to erroneous results of the extent of induction..
The haemoprotein induced by 3MC has been called cytochrome 
P-448 after its CO-binding absorbance maximum (Alvares ^  al, 
1968) but also cytochrome P^-450 (Sladek and Mannering, 1966). 
However, Guenthner and Nebert (1978) have suggested that 
polycyclic hydrocarbons induce both a * cytochrome P^-450’, 
which exhibits a CO-binding peak near 450nm and preferentially 
metabolises benzo(a)pyrene, and a ’cytochrome P-448*, which 
absorbs at 448nm and metabolises acetanilide and N-acetylamino- 
fluorene.
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The pattern of induction described above is generally 
associated with the polycyclic aromatic hydrocarbons. However, 
pnaphthoflavone (BNF) exhibits very similar inducing effects 
to 3MC (Boobis et al^ 1977). The environmental contaminant, 
2,3,7,8-tetrachlorodibenzo-2 -dioxin (TCDD) also exhibits a 
similar specificity of induction to 3MC but is up to 30000 
times more potent (Poland and Glover, 1974).
Inducing agents are commonly classified with reference to 
these two major groups but there are several other classes.
These include the steroids and related compounds (Selye, 1970). 
Pregnenolone-Iboc-carbonitrile (PCN), a synthetic, non-hormonal 
catatoxic steroid, reduces the toxicity of a large number of 
drugs by induction of liver monooxygenase activity (Lu ^  al, 
1972). The spectral characteristics of the microsomal haemo­
protein from PCN treated rats are similar to that from control 
and phenobarbitone treated rats. PCN also causes marked 
proliferation of the endoplasmic reticulum similar to that 
caused by phenobarbitone (Garg ^  1970). However, the
specificity of the induction is dissimilar to that of pheno­
barbitone. PCN causes greater increases in cytochrome P-450 
reductase than in cytochrome P-450 and also has a greater effect 
on ethylmorphine N-demethylase activity than on benzphetamine 
N-demethylase. This is the reverse of phenobarbitone specificity 
(Lu jet al, 1972). Spironolactone, another steroid with little 
or no hormonal activity increases the activities of cytochrome c 
reductase, ethylmorphine N-déméthylation and benzo(a)pyrene 
hydroxylation with no apparent effect on cytochrome P-450 
(Stripp et al, 1971). Stimulation of drug metabolism by 
glucocorticoids will be discussed in section 3.1.
The methylenedioxyphenyl compounds, piperonyl butoxide, 
safrole and isosafrole are both inhibitors and inducers of liver 
cytochrome P-450 dependent monooxygénases (Wagstaff and Short, 
1971). Elcombe et al (1975) suggested that safrole induces a
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similar form of cytochrome P-450 to that induced by 3MC, However, 
pretreatment of rats with isosafrole resulted in the formation 
of a novel species of cytochrome P-450 with molecular weight 
intermediate between those induced by phenobarbitone and 3MC 
(Dickins ^  1978; Fennell ^  1979).
Ethanol also induces a novel species of cytochrome P-450 
(Comai and Gayler, 1973). This form is characterised by the 
preferred substrate, aniline (Villeneuve ^  ad, 1976) and 
selective inhibition by tetrahydrofuran (Ullrich ^  al, 1975).
The pesticides, 1,l-di(£-chlorophenyl)2,2,2-trichloroethane 
(DDT), dieldrin and aldrin exhibit similar inducing properties 
to phenobarbitone (Vainio, 1974; Vainio and Parkki, 1976). In . 
contrast, hexachlorobenzene produces a mixed type of liver 
microsomal enzyme induction (Stonard, 1975; B1ekkenhorst et al, 
1978).
The polybrominated biphenyls (PBB), used as fire retardants, 
have been reported as 3MC type inducers by some authors (Babish 
and Stoewsand, 1977; Goldstein e_t 1979). However, Dent ^  al 
(1978) reported electrophoretic differences in the liver microsomal 
cytochromes P-450 from PBB and 3MC treated rats. The poly­
chlorinated biphenyls (PGB) have been reported as mixed type 
inducers (Alvares and Kappas, 1977; Ryan ^  1977; Yoshimura
et al, 1978). However, commercial preparations of PCB’s are 
impure and any individual PGB inducer may resemble either 
phenobarbitone or 3MG (Poland and Glover, 1977).
Other inducers that cannot be classified as either *3MG 
type* or ’phenobarbitone type* include: caffeine (Lombrozo and 
Mitoma, 1970), coumarins (Ritschel and Lee, 1977), ethoxy quin 
(Kahl and Netter, 1977), 2-acetylaminofluorene (Malejka-Gaganti 
et al, 1978) and ethinyloestradiol (MacKinnon ^  1978). It is
therefore becoming increasingly evident that each inducer may 
stimulate one or more forms of cytochrome P-450. Thomas et ^
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(1976) identified at least six forms of rat liver microsomal 
cytochrome P-450 by their immunochemical properties and this 
number may now be increased to 8-12 forms (Guengerich, 1979). 
Nebert (1979) has even suggested there may be as many forms of 
inducible cytochromes P-450 as there are different chemical 
inducers0
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1.5 ACTIVATION OF DRUG METABOLISM
Induction of monooxygenases is a relatively long term 
control process involving increased ^  novo protein synthesis 
and/or a decreased rate of enzyme degradation and can only be 
demonstrated by pretreatment of animals or in cell cultures. 
Activation of drug metabolising enzymes has been defined by 
Dutton and Burchell (1974) as ”an increase in enzyme activity 
under conditions precluding protein synthesis and directly 
reflecting change in activity of preformed protein molecules 
whose catalytic power is partially or wholly unexpressed".
Many examples of activation (or enhancement) of drug 
metabolising enzyme activity have been reported (Anders, 1971; 
Anders, 1973; Cinti, 1978). In most cases these involve 
stimulation of ^  vitro enzyme activity following the inclusion 
of other chemicals in the reaction mixture and may involve 
multiple enzyme forms. Suggested mechanisms of activation will 
be discussed in section 5.1.2. The three main groups of reactions 
that are susceptible to activation are:
(i) hydroxylation of aromatic amines,
(ii) aryl hydrocarbon hydroxylation,
(iii) glucuronic acid conjugation.
1.5.1. Activation of Aromatic Amine Hydroxylation
E thy1iso cyanide exerts a biphasic effect on aniline
4-hydroxylation, producing an activation dependent on aniline 
concentration at low ethylisocyanide concentrations but inhibition 
above 5mM (Imai and Sato, 1966; Imai and Sato, 1968). Recently, 
Kamataki ^  ^  (1980) observed that cyanide had similar effects.
Metyrapone is a potent inhibitor of adrenal steroid 11p-hydroxylas 
and of the metabolism of hexobarbital and aminopyrine but has a 
biphasic effect on acetanilide hydroxylation (Leibman, 1969). 
Inhibition occurs only at very high concentrations, and the
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reaction is greatly enhanced at lower concentrations.
Anders (1968) reported that acetone markedly enhanced the 
liver microsomal hydroxylation of aniline with maximal enhancement 
of 200-300% occurring between concentrations of 0.45-0.90M 
acetone. Hydroxylation of acetanilide and N-butylaniline were 
also stimulated by acetone whereas no enhancement of 
N-déméthylation of ethylmorphine, N-me thy lanil ine or N, N-dime thy 1- 
aniline or 0-déméthylation of £-nitroanisole was observed.
With the exception of 2-pentanone, which stimulated, other 
structurally related compounds and organic solvents produced 
inhibition or no effect.
Aniline hydroxylation was also enhanced by 2,2* - bipyridine 
and 1,10-phenanthroline (Anders, 1969). In contrast to acetone 
2,2*-bipyridine also stimulated N-deàlkylation of N-methyl- 
aniline and N, N- dime thy lanil ine although it inhibited 
N-déméthylation of ethylmorphine and aminopyrine. Similarly, 
paraoxon enhanced liver microsomal aniline 4-hydroxylation but 
inhibited the microsomal oxidation of hexobarbital and N-déméthyl­
ation of ethylmorphine (Stevens et 1972). Diethylmaleate 
enhanced the microsomal hydroxylation of both aniline and 
acetanilide but inhibited benzphetamine N-déméthylation and 
p-ethoxyacetanilide 0-dééthylation (Anders, 1978).
Several halogen-containing anaesthetics have been shown to 
enhance aniline hydroxylation in rat liver microsomes without 
affecting aminopyrine N-déméthylation (Van Dyke and Rikans,
1970). The anaesthetics included 1,l-difluoro-2,2-dichloro- 
ethylmethyl ether (methoxyflurane), 1,1,1-trifluoro-2,2-dichloro- 
2-bromoethane (halothane) and 1,1,1- and 1,1,2- trichloroethane.
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1.5o2 Activation of Aryl Hydrocarbon Hydroxylation
Wiebel ^  ^  (1971) have studied the effect of otnaphthoflavon
(7,8-benzoflavone, ANF) and organic solvents on liver microsomal
benzo (a)pyrene hydroxylation. ANF produced enhancement of
benzo (a)pyrene hydroxylation at concentrations greater than 
-6
10 M when untreated rats were used. Significant inhibition 
was observed when liver microsomes from 3MC treated rats were 
used. The isomer, pnaphthoflavone (5,6-benzoflavone, BNF) was 
equally effective as a stimulator. The metabolism of 3-hydroxy- 
benzo(a)pyrene was unaffected by ANF in control rat livers but 
markedly inhibited in rats treated with 3MC (Wiebel, 1975). 
However, a derivative of ANF, 4*-benzyloxy-3*-methoxy-7,8 - 
benzoflavone, enhanced by more than two-fold the hydroxylation 
of both benzo(a)pyrene and 3-hydroxybenzo(a)pyrene by' microsomes 
from untreated rats (Wiebel, 1975).
In contrast, the benzo(a)pyrene hydroxylase activity in 
lung, kidney and skin from either control or 3MC treated rats 
was significantly inhibited by the naphthof lavone s (Wiebel ^  al,
1971). Ethanol stimulated kidney and lung microsomal benzo(a)pyre 
hydroxylase activity in both control and 3MC treated rats.
At the same concentration ethanol inhibited liver benzo(a)pyrene 
hydrcxylase activity in control rats and had no effect in 3MC 
treated rats.
ANF activated hydroxylation of benzo(a)pyrene, zoxazolamine 
and antipyrine but had no effect on metabolism of 7-ethoxy- 
coumarin, coumarin and hexobarbital in human liver microsomes 
(Kapitulnik et al^ 1977). The effect on hydroxylation of 
zoxazolamine and antipyrine was biphasic, showing activation 
at 10"*^ M ANF but inhibition at 10 ^M. This is in contrast to 
the biphasic effects of me ty rap one and ethyl iso cyanide on 
aniline hydroxylation which activated at low concentrations
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and inhibited at high concentrations (Anders, 1971; Anders,
1973). Addition of ANF to human liver also stimulated the 
metabolic activation of aflatoxin to mutagens but had no 
effect in rat liver (Buening et 1978). The effects of 
naphthoflavones on carcinogen metabolism have recently been 
reviewed by Wiebel (1980).
1.5.3 Activation of other Phase I Reactions
Simultaneous incubation of aniline and phenylbutazone 
with rat liver microsomes caused increased activity of phenyl­
butazone hydroxylation but decreased the activity of aniline 
hydroxylation (Kitagawa et al, 1971). Similarly, the predominant 
hydroxylation product of aniline, 4-aminopheno 1, also increased 
phenylbutazone hydroxylation.
The polyamines, spermine and spermidine, increased the 
2-hydroxylation of oestradiol in liver microsomes of both 
male and female rats (Jellinck and Perry, 1967). More recently. 
Chapman (1976) reported that these polyamines also increased 
the microsomal N-déméthylation of ethylmorphine.
ANF has been found to activate enzymes other than aryl 
hydrocarbon hydroxylase. Laurie acid (o-l)-hydroxylation was 
stimulated by ANF in human liver microsomes, whereas a?.-hydroxyl­
ation was inhibited (Okita ^  1979). ANF also activated
both microsomal and soluble 6-hydroxymethylbenzo(a)pyrene 
synthetase of rat liver and lung (Sloane, 1975).
1.5.4 Activation of UDP-Glucuronyltransferase
Dutton (1966, 1971, 1977) has published several excellent 
reviews of UDP-glucuronyltransferase (GT; EC 2.4.1.17). From 
these sources, activation of GT has been summarised here.
Fresh ('native') microsomes or homogenates prepared rapidly 
exhibit less GT activity than do activated preparations. It is
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generally considered that the ^  vivo activity of GT is similar 
to that found in fresh microsomes and may be activated by 
endogenous activators. The active site of GT is probably 
behind a lipophilic barrier reducing the accèssability of the 
cofactor, UDP-glucuronic acid and/or of the substrates (Berry 
et al, 1975). Alternatively, activation may be explained by 
conformational changes (Zakim and Vessey, 1976).
Activation of GT may be achieved in many diverse ways, 
including:
a) Mechanical disruption such as sonication, blending, grinding 
with glass - possibly causing mechanical rupture of GT-containing 
vessels.
b) Storage - either of whole liver, or of microsomes or 
homogenates. The mechanism may be due to phospholipase action 
releasing activators or to formation of peroxide activators.
c) Surfactants - anionic, cationic and non-ionic detergents 
may all activate GT.
d) Chaotropic agents and organic solvents - n-hexane, chloroform, 
acetone and diethylether activate but alcohols inhibit.
e) Sulphydryl reagents - GT conformation in fresh microsomes 
may be constrained by hydrogen bonds near to thiol groups on 
the GT protein itself or in a neighbouring constraining protein.
In this circumstance thiol-bio eking agents would activate GT .
f) Diethylnitrosamine - activated GT both vitro and m  vivo 
towards certain substrates only but also increased activation
by other compounds, possibly by removal of a membrane constraint.
g) Trypsin - believed to solubilise enzymes on the outer 
surface of the microsomal vesicle thus increasing accès sability 
to GT which may be on the inner surface.
h) Phospholipases and phospholipid - produce complex effects 
dependent of the species and substrate, the mechanisms are as 
yet unknown.
i) Fatty acids - again, like other compounds reducing membrane 
permeability, may inhibit ac activate depending on the
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concentration, time of action and the previous history of the 
GT preparation.
j) UDP-N-Acetylglucosamine - an ideal physiological modifier 
of GT (towards 4-nitropheno 1 in guinea-pig liver) as it activates 
the forward reaction, inhibits the reverse reaction, limits 
end-product inhibition and conserves substrate specificity, 
k) Reactants and products - at low UDP-glucuronic acid levels 
several glucuronides activate GT by binding to an allosteric 
site on the enzyme.
1) Other activating processes - ATP, NADPH, alkaline pH, lipid 
peroxides.
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1.6 BIPHENYL
Biphenyl is a fungistat, widely used for preserving citrus 
fruits and in carpets. Data on the toxicology of biphenyl are 
not extensive, although Hakkinen ^  ^  (1973) reported the death 
of one worker and eight cases of severe poisoning following 
chronic biphenyl inhalation. The metabolism of biphenyl has 
been elucidated in great detail. The main route of excretion 
of biphenyl metabolites in the rat is via the urine. Fig. 1.2 
shows the main metabolites that have been identified after 
treatment of rat urinary conjugated products with glucuronidase 
and aryl sulphatase (Meyer and Scheline, 1976; Halpaap ^  al, 
1978). Halpaap et ^  (1978) also isolated 4,4'-dihydroxy-3- 
methylthiobiphenyl, two hydroxydiols and another trihydroxy- 
biphenyl of unknown structure. 4-Hydroxylation appeared to 
be the major metabolic route of not only biphenyl itself but 
also its other hydroxylated products, thus 4,4'-dihydroxybiphenyl 
was the most abundant secondary metabolite (Meyer and Scheline, 
1976).
Biphenyl metabolism has also been studied in pig (Meyer 
^  1975), guinea-pig, rabbit (Meyer, 1977; Raig et al,
1976), marine organisms (Meyer and Bakke, 1977) and fungi 
(Dodge ^  1979 ) and shows both qualitative and quantitative
species differences in its metabolic profile. Raig ^  ^
(1976) also demonstrated that biphenyl metabolism shows variation 
with age in rabbits, guinea-pigs and rats, and with strain 
and sex in rats.
Numerous m  vitro studies have also been performed. It 
has long been suggested that the 2- and 4-hydroxylating enzymes 
are different. Creaven ^  al (1965) first demonstrated that 
2-hydroxylation decreases in the maturing rat. Basu _et ^
(1971) found that biphenyl 2-hydroxylation was undetectable in 
rats older than 52 days. Phenobarbitone preferentially increased
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Fig* 1.2 Proposed Metabolic Pathway of Bipheiiyl in the Rat. 
Major routes are indicated by thick arrows. Broken arrows 
indicate possible but not verified conversions in the rat 
(Meyer and Scheline, 1976; Halpaap ^  1978).
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—  26 -
4-hydroxylation with little or no effect on 2-hydroxylation 
whereas the carcinogenic polycyclic aromatic hydrocarbons 
preferentially induced 2-hydroxylation (Creaven and Parke, 1966). 
Thus biphenyl is often used as a model drug metabolism substrate 
for the two major forms of induction. Recently Billings and 
McMahon (1978) demonstrated that 3-hydroxylation is induced 
more markedly by 3MC and BNF than by phenobarbitone. These 
workers suggested that 3-hydroxylation is formed by a pathway 
different from that of either 2- or 4-hydroxybiphenyl and may 
be via a direct hydroxylation pathway rather than via an epoxide.
Creaven and Parke (1966) originally suggested that there 
was a correlation between the carcinogenicity of polycyclic 
hydrocarbons and their induction of the hepatic microsomal 
ehzyme responsible for biphenyl 2-hydroxylation. A similar 
increase in 2-hydroxylation was found following the vitro 
addition of a number of carcinogenic but not non-carcinogenic 
chemicals to rat, hamster or mouse liver microsomes while other 
liver microsomal drug metabolising monooxygenases were not 
affected (McPherson ^  1974; McPherson ^  1976a). A
specific increase in biphenyl 2-hydroxylation was also apparent 
2h after intrap eritoneal administration of safrole or benzo (a)- 
pyrene to rats and appeared to be similar in nature to that 
observed vitro (McPherson al. 1976b). It was suggested 
that carcinogens, or their metabolites, may activate a latent 
form of cytochrome P-450 and that this could form the basis of 
a short term screening test for carcinogens (McPherson ^  al. 
1974; Parke, 1977).
Tredger et ^  (1976a) observed that some glucocorticoids 
also activated biphenyl 2-hydroxylation activity in rat liver 
microsomes and that the most pronounced effect was obtained 
with betamethasone.
These early studies all employed the fluorescence detection 
method for 2- and 4-hydroxybiphenyl (Creaven et al. 1965).
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When determining both metabolites the fluorescence of the 
predominant 4-hydroxybiphenyl overlaps that of 2-hydroxybiphenyl 
thus reducing the sensitivity for the latter. Also many 
carcinogens and their metabolites are. highly fluorescent and 
may interfere with the determination of 2-hydroxybiphenyl (Tong 
et al, 1977). As biphenyl and the test carcinogen may both 
be metabolised by cytochrome P-450 and may each cause competitive 
inhibition of the other's metabolism, the fluorescence controls 
are inadequate. The data of McPherson ^  al may therefore be 
subject to error. Indeed, Vîÿndham and Safe (1978) found inhibitio 
of both 2- and 4-hydroxylation of biphenyl after incubation of 
biphenyl with liver microsomes and carcinogenic polycyclic 
hydrocarbons using thin-layer chromatographic analysis of the 
metabolites.
Recently, a gas-liquid chromatography assay has been 
developed that allows detection of 2-, 3- and 4-hydroxybiphenyl 
(Billings and McMahon, 1976). Using this method the carcinogens 
benzo (a) pyrene, 3MC and çnaphthylamine were found to inhibit
2-hydroxylation although ANF increased the activity (Billings 
and McMahon, 1978). A high pressure liquid chromatography 
(h.p.l.c.) assay for the hydroxybiphenyls has also been developed 
(Burke and Prough, 1977; Burke ^  al, 1977). This method is 
more sensitive and less time-consuming than the gas-liquid 
chromatography assay and has therefore been used routinely for 
the work presented in this thesis.
In preliminary experiments using this h.p.l.c. technique, 
activation of biphenyl 2-hydroxylation by carcinogens was not 
observed (D.J. Benford, M.D. Burke, J.W. Bridges and D.V. Parke, 
unpublished data). The object of this thesis became to study 
the activation of biphenyl 2-hydroxylation by glucocorticoids, 
including an investigation of sex, age and tissue differences 
and an attempt to elucidate the mechanism by comparison with 
other known activations, by inhibition studies and by comparison 
of in vitro models with in vivo.
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CHAPTER TWO
MATERIALS AND METHODS
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2.1 MATERIALS
2.1.1 Animais ^
Maie Wistar albino rats (80-120g), supplied by the 
University of Surrey Breeding Unit, were used unless otherwise 
stated. Syrian Golden hamsters (60g) were obtained from 
W.Oo Wright (Essex). All animals were acclimatised for a 
minimum of 3 days on 'Sterolit* bedding (Engelhard, New Jersey, 
U.S.A.) and allowed access to food (Laboratory Diet No. 1, 
Spillers Ltd., Croydon) and water, under conditions of constant 
temperature (22°), humidity (56%) and lighting (I2h darkness).
Human liver microsomes prepared from postmortem liver 
samples obtained from kidney donors were kindly supplied by 
Dr. Do So Davies (Royal Postgrad. Med. School, London).
2.1.2 Chemicals
Biphenyl (BDH Ltd., Poole, Dorset) was recrystallised
otwice from ethanol to give a product, m.p. approx. 70 . 
Betamethasone was purchased from Sigma (Poole, Dorset). Other 
steroids were gifts from Dr. J. Chakraborty and Dr. A.M. Symons 
(Dept, of Biochemistry, University of Surrey), from Glaxo 
Laboratories Ltd. (Greenford, Middlesex) and from G.D. Searle 
& Co. (High Vtycombe, Bucks.). Benzo (a)pyrene and ANF were 
purchased from Aldrich Chemical Co. (Gillingham, Dorset). 
Authentic 3-hydroxybenzo(a)pyrene was a gift from Dr. G.M. Cohen 
(Dept, of Biochemistry, University of Surrey) as supplied by 
the Carcinogenesis Research Program (National Cancer Institute, 
Bethesda, U.S.A.). H-Benzo(a)pyrene was obtained from the 
Radiochemical Centre (Amersham, Bucks.)
D-L-Trisodium isocitrate, NADP and NADPH were purchased 
from Sigma (Poole, Dorset) as were the enzymes, collagenase 
(type IV; EC 3.2.24.3), hyaluronidase (type II; EC 3.2.1.35)
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and aryl sulphatase (type HI, EC 3.1.6.1), Isocitrate 
dehydrogenase (EC 1.1.1.42) was purchased from Boehringer 
Mannheim Co. (Germany) and pure p-glucuronidase ('Ketodase*;
EC 3.2.1.31) was purchased from General Diagnostics (Eastleigh, 
Hants). Cumene hydroperoxide was obtained from Fluka AG 
(Germany). Sodium cholate and dithiothreitol were purchased 
from Sigma (Poole, Dorset).
Acetonitrile and 2,2,4-trimethyIpentane (Fisons, 
Loughborough, Leics.) were h.p.l.c. grade. All other chemicals 
were of at least analytical reagent grade and were used as 
supplied.
2.1.3 Instruments 
Centrifuges
An MoSoE High Speed 18 centrifuge was used for preparation 
of the post-mitochondrial supernatant from homogenised tissues. 
Microsomal fractions were prepared using either a Beckman L5-65 
centrifuge (170 OOOg, 40min) or an M.S.E. Superspeed 50 
centrifuge (104 OOOg, 60min).
The h.p.l.c. instrument consisted of Cons tame trie I and IIG 
double reciprocating pumps with Gradient Master 1601, Rheodyne 
7120 injection valve and UVIII Monitor 1203 (254nm) and was 
supplied by Laboratory Data Control (Stone, Staffs.).
Spectrophotometers
Spectrophotometric measurements were made on a Cecil CE 272 
spectrophotometer or on a dual beam Pye-Unicam SP 1800 recording 
spectrophotometer.
Fluorescence measurements were made on a Perkin Elmer MPF3 
spectofluorimeter.
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2.2 METHODS
2.2.1 Animal Pretreatment ^
Monooxygenase activity was induced in rats by intrap eritoneal 
(i.p.) injection of sodium phenobarbitone (80mg/kg as a Ibmg/mg 
solution in saline), 3MC (20mg/kg as a 5mg/ml solution in 
c o m  oil) or PCN (50mg/kg as a 5mg/ml suspension in c o m  oil) 
once daily for three days. The rats were sacrificed by cervical 
dislocation approximately 24h after the final dose. Control 
animals were either untreated or received an equal volume of 
saline or corn oil.
Betamethasone was administered i.p. as a single dose 
(I4mg/kg as a suspension in c o m  oil) (Tredger ^  1976a)
and the rats sacrificed at predetermined intervals as described 
in the results. Control animals were injected with an equal 
volume of c o m  oil.
2.2.2 Microsomal Preparations 
Liver
All animals were killed by cervical dislocation between 
8.30 and 10.00a.m., except after betamethasone pretreatment.
Livers were excised, weighed and scissor-chopped in 3 volumes 
of ice-cold KCl (1.15%) in sodium potassium phosphate buffer 
(O.IM; pH 7.6). All subsequent procedures were performed at 
4°. The liver was homogenised using a Potter-Elvehjeim 
homogeniser (size C; 2 strokes of 9s each). The homogenates 
were centrifuged (15 OOOg, 20min), the supernatants removed 
and centrifuged again (170 OOOg, 40min or 104 OOOg, 60min) 
to sediment the microsomal fraction. The resultant pellet was 
washed by resuspending in buffered KCl and the second centrifuga­
tion was repeated.
For immediate use, the microsomal pellet was resuspended
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in phosphate buffer (O.IM; pH 7.6) to give approx. 20mg of 
microsomal protein per ml. If the microsomes were to be frozen 
for future use the pellets were re suspended to the sam^ protein 
concentration in Tris-HCl buffer (20mM; pH 7.6) containing 
sucrose (0.25M) and ethylenediaminetetraacetic acid (EDTA;
5.4mM) and stored at -40°. When required they were allowed to 
thaw slowly. Under these conditions the biphenyl hydroxylation 
activities did not alter significantly.
Extrahepatic tissues
Rat small intestinal microsomes were prepared by the method 
of Shirkey ^  ^  (1979).
Wistar albino rats (250-300g) were killed by cervical 
dislocation. The small intestine was severred proximal to 
the pyloris and flushed with ice-cold NaCl (0*9%). The end 
was clamped with arterial forceps and a length ( 100cm) of 
small intestine carefully dissected out. All subsequent steps 
were performed at 4°. Three sections (20cm) of the intestine 
were inverted over rods and vibrated (60s) in NaCl (0.9%) using 
a Vibromixer (Model El, Chemag, Zurich). This step removes 
food particles and mucus. The intestine was then vibrated 
(30min) in NaCl (0.9%) containing EDTA (5mM) to harvest the 
villus cells. The cells were washed four times with NaCl (0.9%), 
weighed (approx. 2g) and homogenised in hypotonic sucrose (75mM) ; 
4ml/g wet wt. ) using a Potter Elvehjeim homogeniser (size B,
8 strokes). The homogenate was immediately readjusted to 
isotonicity by addition of an equal volume of sucrose (0.5M), 
diluted with sucrose (0.3M, 16ml/g wet wt.) and centrifuged 
(lOOOg, 5min). The pellet, containing the brush-border nuclei 
fraction, was washed with sucrose (0.3M, 3 x 10ml) and the 
supernatants combined. Centrifugation (15 OOOg, lOmin) removed 
the mitochondrial fraction and further centrifugation (104 OOOg, 
60min) yielded the microsomal fraction. This was resuspended
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in phosphate buffer (O.IM; pH 7.6) to a concentration of lOmg 
of protein per ml and used immediately.
Rat lung microsomes were prepared as for liver except that 
it was necessary to chop the lung tissue very finely with 
scissors before homogenisation (Potter-Elvehjeim, size B;
10 strokes)
Rat kidney cortex microsomes were prepared essentially 
by the method of Orrenius ^  al (1973). Kidneys were removed 
and washed in KCl (1.15%), bisected longitudinally and the fat 
and cortical medulla removed. Homogenisation and centrifugation 
were the.same as for liver.
2.2.3 Microsomal Hydroxylation of Biphenyl
An incubation mixture was prepared containing an NADPH 
generating system consisting of isocitrate (7.0jumol), NADP 
(l.Opmol), isocitrate dehydrogenase (0.8U) and MgSO^ (lOpmol) 
in sodium potassium phosphate buffer (O.IM; pH 7.6) (Burke and 
Bridges, 1975). Steroids were added in dimethylformamide (DMF, 
lOpl), DMF alone being added to controls. The reaction was 
started by addition of microsomal protein (4mg) and preincubated 
for 60s in a shaking water bath (37°, 120 oscillations/min) 
before addition of biphenyl (0.5ml, 4mM) in Tween 80 (1% w/v) 
giving' a biphenyl concentration of ImM in the total volume of 
2ml. Incubations continued for either 5min (liver microsomes) ' 
or 15min (extrahepatic microsomes) and the reaction stopped by 
addition of HCl (0.5ml, 4M). Metabolism was linear during the 
above incubation times.
For the kinetic data, the biphenyl concentration in the 
incubations was in the range, 0.1 to l.OmM, Tween 80 was constant 
(0.25%).
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For inhibition studies, me ty rap one, SKF 525A and ANF were 
added to the reaction mixtures as solutions in DMF prior to 
preincubation. Metabolism was measured in the presence of 
inhibitor, betamethasone, inhibitor plus betamethasone or 
solvent alone. DMF concentration was 1% in all incubations 
and had no significant effect on the metabolism.
In experiments studying the effect of the detergent Brij 35 
on biphenyl hydroxylation. Tween 80 was omitted and biphenyl 
was added in DMF to the same final concentration (l.OmM).
Again DMF did not exceed 1%.
2.2.3.1 H.p.l.c. Determination of Hydroxybiphenyls
Biphenyl metabolism was routinely assayed by the h.p.l.c. 
method of Burke and P rough (1977) using an amino - bonded phase 
column (25cm, 5pm particle size). APS-Hypersil (Shandon Southern 
Ltd., Runcorn, England) and Spherisorb S-5NH^ (Phase Sep. Ltd., 
Queens ferry, Wales) proved equally efficient.
The hydroxybiphenyl s were extracted into tr imethy Ip entane 
(7ml) containing isoamyl alcohol (1.5%) on a rotary shaker 
(lOmin). After centrifuging (lOOOg, 5min) the organic phase 
(6ml) was removed, filtered using a Teflon filter (0.45pm, 
Millipore) and evaporated to dryness. The extracts were 
redissolved in 50 to lOOpl of trimethylpentane-isoamyl alcohol- 
acetonitile (100:12:8) and an aliquot (30 to 50pl) injected 
into the h.p.l.c. instrument in isochratic mode. The sample 
was eluted with tr imethy Ip entane-isoamyl alcohol-acetonitrile 
(100:12:8) at a flow rate of 1.5ml/min. The elution times 
of 2-, 3- and 4-hydroxybiphenyl were 5.5, 7.0 and 8.0 min, 
respectively.
The occurence of interfering peaks was checked by substrate 
blanks, with biphenyl added after incubation was stopped. 
Standards were prepared in' a similar fashion with 2-, 3- and
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4-hydroxybiphenyl (5nmol) also added after the acid. The 
hydroxybiphenyls in the samples were quantitated by comparison 
with the peak heights of the standards.
2.2.3.2 Fluorescence Determination of Hydroxybiphenyls
The h.p.l.c. assay was used in preference to fluorimetry 
since it is more sensitive and specific and allows detection 
of 3-hydroxybiphenyl. However, a metabolite of ANF cochromato­
graphed with 2-hydroxybiphenyl. Therefore when measuring 
biphenyl hydroxylation in the presence of ANF an adaptation of 
the fluorimetric method of Creaven et al (1965) was used.
Incubations were performed as previously described. The 
hydroxybiphenyl s were extracted into trimethylp entane (7ml) 
containing isoamyl alcohol (1.5%) on a rotary shaker (lOmin).
After centrifuging (lOOOg, 5min), an aliquot (2ml) of the 
organic phase was removed and back-extracted (lOmin) into NaOH 
(5ml, O.IM). The tubes were centrifuged (lOOOg, 5min) and the 
organic layer aspirated off. The aqueous layer was then further 
extracted into trimethylp entane (2ml) containing isoamyl alcohol 
(1.5%), centrifuged and the organic layer aspirated off. This 
step was introduced to reduce contamination by biphenyl.
Finally, an aliquot (2ml) of the aqueous phase was mixed with 
succinic acid (0.5ml, 0.25M) in a cuvette and the fluorescence 
measured immediately at the maximum wavelengths of 2- and
4-hydrox}’'biphenyl (Aex 290, X em 410; A ex 274, Aem 330, respectively 
Blanks were incubations with biphenyl added after the acid. 
Individual 2- and 4-hydroxybiphenyl standards were also carried 
through the procedure..
The fluorescence at A 274, 330nm is due to 4-hydroxybiphenyl 
alone so this can be calculated directly. But 4-hydroxybiphenyl 
also fluoresces at the maxima of 2-hydroxybiphenyl and must be 
Corrected for in the calculation of the latter.
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2.2.4 Microsomal Hydroxylation of Benzo(a)pyrene
2.2.4.1 The Aryl Hydrocarbon Hydroxylase Assay ^
Benzo(a)pyrene is metabolised to a large number of products 
by an enzyme, or group of enzymes, known as aryl hydrocarbon 
hydroxylase (AHH, EG 1.14.14.2). The fluorimetric AHH assay 
measures only the fluorescent phenolic metabolites, in particular
3- and 9-hydroxybenzo(a)pyrene. A modified version of the method 
of Dehnen ^  ^  (1973) has been used.
A typical incubation mixture contained an NADPH generating 
system consisting of isocitrate (3pmol), NADP (0.5;jmol), 
isocitrate dehydrogenase (0.8U) and MgCl^ (5pmol) in Tris-HCl 
buffer (O.IM, pH 7.4). Betamethasone or ANF was added in DMF 
(b.5%) and approximately 0.3mg of microsomal protein was added 
to give a final volume of 1ml. The reaction mixtures were 
preincubated for 60s in a shaking water bath (37°, 120 oscilla­
tions /min) before addition of benzo(a)pyrene (O.l^ol) in 
DMF (2pl). The incubation continued for 5min (liver microsomes) 
or 15min (extrahepatic microsomes) and was stopped by addition 
of ice-cold acetone (1ml). Blank samples were incubated without 
benzo(a)pyrene which was added after the acetone. The tubes 
were then centrifuged (lOOOg, 5min) to precipitate the protein.
Within 2h, an aliquot (0.5ml) of the acetone solution was 
mixed with trie thy lamine (2.5ml, 7.5%) in a cuvette and the 
fluorescence measured immediately (excitation, 467nm; emission, 
518nm). A standard plot of authentic 3-hydroxybenzo(a)pyrene 
was prepared with reference to quinine sulphate (O.lpg/ml in 
0.05M H^SO^). Quinine sulphate was used as a reference in 
subsequent experiments.
2*2.4.2 H.p.l.c. of Benzo(a)pyrene Metabolites
Incubations were performed as in section 2.2.4.1 except
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that uniformly labelled H-benzo(a)pyrene (75mCi/ramol) was used 
in a total volume of 2ml. The reaction was stopped by addition 
of e thy lace tat e (7ml) and extracted on a rotary shaker 30min).
An aliquot (6ml) of the organic phase was removed, dried over 
anhydrous sodium sulphate, spiked with non-radioactive authentic 
benzo(a)pyrene metabolites, filtered and evaporated to dryness.
The residue was redissolved in methanol (100;ul) and the metabolite: 
separated using the h.p.l.c. method of Selkirk ^  (1974).
A reverse-phase ODS column (25cm; Phase Sep. Ltd.,
Queens ferry, Wales) was used. A linear gradient (50min) from 
methanol/water (1:1) to methanol/water (4:1) and a flow rate of 
Iml/min were set. When the gradient was complete the solvent 
was changed to 100% methanol to elute the benzo (a)pyrene.
Fractions (2/min) were collected in minivials, 4ml of scintilla­
tion cocktail(2,5-diphenyloxazole, 0.4%; l,4-bis-2-(4-methyl-
5-phenyloxazoyl)-benzene, 0.01% in sulphur-free toluene) was 
added. Radioactivity was measured in a Packard Tricarb 2425 
liquid scintillation counter. Elution of radioactivity was 
compared with the uv chromatogram of the authentic standards.
2.2.5 Aniline 4-Hydroxylase
The spectrophotometric method of Schenkman ^  al (196%.) 
was used.
The NADPH generating system described in section 2.2.3 
was used. Microsomal protein (lOmg) was added and preincubated 
for 60s in a shaking water bath (37°, 120 oscillations/min).
The reaction was started by addition of aniline HCl (0.5ml,
40mM) to give a total volume of 2ml. Incubation was continued 
for lOmin then stopped by addition of ice-cold trichloracetic 
acid (1.0ml, 20%). The tubes were centrifuged to precipitate 
the protein and an aliquot (iml) of clear supernatant added to 
an equal volume of freshly prepared phenol (l%) in NaOH (0.5M), 
followed by addition of NagCOg (iml, l.OM). The colour was
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allowed to develop (30min, room tempo) and then the absorbance 
was measured (630nm)«,
Blanks were prepared by addition of the trichloracetic 
acid before the aniline. Standards were blanks with 4-amino- 
phenol (lOOnmol) added. Acetone (0.068 to 1.36M) was added 
before preincubation to activate the enzyme. Betamethasone 
(10  ^ to 10 ^M) in DMF (lOpl) was also added before preincubation.
2*2.6 Ethoxycoumarin 0-Deethylase
The direct fluorimetric method of Ullrich and Weber (1972) 
was used.
The reaction mixture (2ml), prepared in a cuvette, contained 
microsomal protein (2mg), sodium potassium phosphate buffer 
(O.IM, pH 7.6) and 7 - ethoxycoumarin (0.4pmol). Betamethasone 
(10  ^to 10 ^M) was added in DMF (lOpl). A fluorescence baseline 
(excitation, 370nm; emission, 450nm) was recorded with the 
cuvette holder heated to 37°. After preincubation in the 
fluorimeter for 2min, the reaction was started by addition of 
NADPH (Ipmol) and the change in fluorescence was recorded for 
5min*
2.2.7 Ethoxyresorufin 0-Deethylase
The direct fluorimetric assay of Burke and Mayer (1974) 
was used.
The reaction mixture (2ml), prepared in a cuvette, contained 
microsomal protein (0.4mg) and ethoxyresorufin (O.Snmol) in 
sodium potassium phosphate buffer (O.IM, pH 7.8). A fluorescence 
baseline was recorded (excitation, 550nm; emission, 582nm) at 
37°. After 60s, NADPH (SOOnmol) was added and the increase in 
fluorescence was recorded. Resorufin (O.lnmol) was used as a 
standard.
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2.2.8 Ethylmorphine N-Demethylase
The spectrophotometric method of Holtzman ^  ^  (1968) 
was used. ^
The NADPH generating system was as used in section 2.2.3. 
with the addition of semicarbazide HCl (loOpmol)o Microsomal 
protein (4mg) was added and preincubated in a shaking water bath 
(37°, 120 oscillations/min) for 60s. The incubation was 
started by addition of ethylmorphine (0.5ml, 4mM) giving a 
total volume of 2ml, and continued for 5min. The reaction was 
stopped by addition of ice-cold ZnSO^ (0.5ml, 25%) followed by 
saturated Ba(0H)2 (0.5ml). After centrifuging (lOOOg, 5min), 
an aliquot (iml) of the clear supernatant was added to freshly 
prepared Nash reagent (2ml; 30% ammonium acetate containing 
0.4% acetylacetone)o The colour was allowed to develop (30min, 
60°) then measured at 415nm.
A standard plot was prepared by addition of formaldehyde 
(iml, 50-200nmol) to Nash reagent (2ml) and incubation as 
before.
2.2.9 . UDP-Glucuronyltransferase
UDP-Glucuronyltransferase (EC 2.4.1.17) is the enzyme, or 
group of enzymes, responsible for the conjugation of steroids, 
bilirubin and xenobiotics to glucuronic acid. Glucuronyl trans f er­
ase activity may be activated by many agents including non­
ionic detergents (see section 1.5.4). The detergent Brij 35 
was used as a model activating agent by Berry et al (1975) 
whose method was used for this work.
A typical reaction mixture contained 4-aminophenol (0.5pmol), 
microsomal protein (l.Omg) and MgCl^ (Ipmol) in Tris-HCl buffer 
(OolM, pH 7.6). The reaction was started by addition of 
UDP-glucuronic acid (0.5pnol) to give a total volume of 0.25ml 
and was incubated for lOmin in a shaking water bath (37°,
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120 oscillations/min). Substrate was omitted from blanks 
and UDP-glucuronic acid was omitted from standards. Activated 
preparations included Brij 35 (0.1%). The reaction was^ stopped 
by addition of ice-cold trichloracetic acid (5ml, 2%). After 
centrifuging (lOOOg, 5min), the clear supernatant was added 
to KOH (0.1ml, lOM) containing EDTA (lOmM), The absorbance 
of the samples was measured immediately at 400nm. The disappear­
ance of 4-aminophenol was calculated and assumed to be equal 
to the rate of glucuronidation.
2.2.10 Cytochrome P-450
The method of Omura and Sato (1964) was used. Microsomes
were diluted to Img protein/ml in phosphate buffer (0,IM, pH 7.6)
afid placed in two cuvettes. Sodium dithionite (approx. lOmg)
was added to each cuvette and a baseline was recorded from
390nm to 550nm on a dual beam spectrophotometer. Carbon
monoxide was bubbled through the sample cuvette for 30s and
the difference spectrum was again recorded from 390nm to 550nm.
Cytochrome P-450 was calculated from the difference in absorbance
between the peak at 450nm and the trough at 490nm, assuming
-1 -1an extinction coefficient of 91mM cm .
2.2.11 Cytochrome c reductase (EC 1.6.2.4)
An adaptation of the method of Williams and Kamin (1962) 
was used.
The reaction mixture in the sample cuvette contained 
cytochrome c (O.ljimol) and microsomal protein (0.3mg) in potassium 
phosphate buffer (2.9ml, O.IM, pH 7.4). The reference cuvette 
contained the same in a total volume of 3.0ml. The cuvettes 
were allowed to preincubate at 25° for 5min, then the reaction 
was started by addition of NADPH (Of, 1ml, 3mM) to the sample 
cuvette. The change in absorbance at 550nm was monitored and 
the activity was calculated from the initial velocity assuming
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an extinction coefficient of 18.5mM" cm"
To test the effects of betamethasone on cytochrome c reductas» 
activity, betamethasone (10 in 15pl DMF) was added tb each 
cuvette before preincubation.
2.2.12 Protein Estimations
An adaptation of the method of Lowry ^  al (1951) was used.
Microsomal suspensions were diluted (1/200) with NaOH 
(0.5M)o Freshly prepared Lowry reagent (5ml; 2% Na2CO^/2% 
potassium sodium tartrate/1% CuS0^.5H20; 100:1:1) was added to 
aliquots of diluted micro somes (iml). The tubes were mixed 
thoroughly and left for lOmin before addition of Folin-Ciocalteu 
reagent (0.5ml, 1/3 dilution) and mixing again. The colour 
was allowed to develop (30min, room temp.) then the absorbance 
was measured at 720nm.
A standard plot was prepared on each occasion by dilution 
of bovine serum albumen (0 to 200;ig/ml) in NaOH (0.5M) and 
then treating as for the samples,
2.2.13 Isolation of Viable Rat Hepatocytes
Hepatocytes were isolated according to the method of 
Fry at ^  (1976),
Male rats (60-80g) were sacrificed by cervical dislocation.
2"i"The livers (approx, 3g) were removed into Dulbecco’s Ca - and 
2+
Mg - free phosphate buffered saline (PBS’A; Paul, 1973), The 
lobes were dried briefly on a filter paper supported on a sheet 
of glass and cut with a microtome blade (Swann-Morton PM40, 
Swann-Morton, Sheffield) into slices (0.5 to 1.0mm). The slices 
from one liver were washed into a conical flask (250ml) with 
PBS*A (lOml) and the flask was shaken for lOmin in a shaking 
water bath (37°, 90 oscillations/min). The supernatant was
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discarded and the slices were washed twice more. This was
followed by two washes (lOmin) with PBS’A ( 10ml) containing
ethylene glycol-bis-(p-aminoethylether)tetraacetic acid (EGTA;
0.5mM). After carefully removing the EGTA, each flask received 
24-
Hanks Mg - free balanced salt solution (lOmI; Paul, 1973) 
containing CaCl^ (5mM) and collagenase/hyaluronidase (5mg/lOmg) 
and was incubated for bOmin in a shaking water bath (37°, •
120 oscillations/min). The cell suspension was filtered through 
Bolting cloth (125pm pore size, John Staniar & Co., Manchester) 
to remove clumps of cells and undigested material. The filtrate 
was centrifuged (50g, 60s) and the pellet washed twice in PBS*A. 
The cells were finally resuspended in L-15 medium (Leibovitz, 
1963) supplemented with foetal calf serum (10%).
The viability of the cells was assessed by their ability 
to exclude the dye, trypan blue. Cell suspension (0.25ml) was 
added to trypan blue solution (0.1ml, 0.4%), mixed thoroughly 
and counted in a Neubauer Improved Counting Chamber (Gelman 
Hawkesley. Lancing, Sussex), Viable cells were expressed 
as a percentage of the total cell count. The total yield of 
viable cells was calculated as follows:
viable cell count x 1.4 x 10^ cells/ml.
Cells were diluted as required in supplemented L-15 medium.
2.2.14 Biphenyl Metabolism in Isolated Hepatocytes
Hepatocytes with a viability of greater than 85% were 
isolated as above and resuspended to a concentration of 2 x 10
6
cells/ml. Following the method of Wiebkin et al (1976), 
incubations contained cell suspension (5ml, 10^ cells), biphenyl 
(70pM) and DMF (lOpl) in conical flasks (50ml). Betamethasone 
(or ANF) was added to test incubations in DMF (lOpl) so a total 
of 20pl DMF was included in all flasks. Blanks were incubated 
without biphenyl. Standards were blanks with hydroxybiphenyls
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(5ranol) added after incubation. The flasks were incubated for 
30min in the shaking water bath then the reaction stopped by 
immersing the flasks in ice. There was no significant decrease 
in cell viability in either controls or tests during this period.
Aliquots of the cell suspensions were subjected to different 
deconjugation procedures as summarised in Fig. 2.1. Extractions, 
h.p.loCo and fluorescence detection were as previously described 
(section 2.2.3.1, 2.2.3.2).
2.2.15 Benzo(a)pyrene Metabolism in Isolated Hepatocytes
Hepatocytes were isolated as described above and resuspended 
to a concentration of 2 x 10^ cells/ml. One ml of cell 
suspension was placed in conical flasks (lOml) and benzo(a)pyrene 
(SOnmol in 2pl DMF) was added. Betamethasone or ANF were added 
to test incubations in DMF (5pl), DMF alone was added to controls. 
Blanks were incubated without benzo(a)pyrene, with and without 
betamethasone and ANF. The flasks were incubated for 20 min 
in the shaking water bath then the reactions stopped by immersing 
the flasks in ice.
The hydroxylated benzo(a)pyrene metabolites were extracted 
by the method of Nebert and Gelboin (1968).
The cell suspension was extracted w/th n-hexane (5ml) for 
lOmin. After centrifuging to separate the phases, the aqueous 
phase was reserved and the organic» phase (2ml) was back-extracted 
into NaOH (l.OM) for lOmin. The tubes were again centrifuged 
and the n-hexane aspirated off. The fluorescence of the alkaline 
phase was measured immediately (excitation, 467nm; emission, 
518nm). A standard plot of authentic 3-hydroxybenzo(a)pyrene 
was prepared initially and quinine sulphate (O.lpg/ml in 0.05M 
H^SO^) was used as a reference.
The remaining n-hexane was aspirated off the reserved cell 
suspension which was then subjected to the same deconjugating
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Fig, 2.1 Deconjugation Procedure for Biphenyl Metabolites 
Produced by Isolated Rat Hepatocytes.
Hepatocyte incubation (5ml) 
on ice
2 X 1ml aliquotsi
add 1ml cone HCl 
boil for Ihi
extracti
organic phasei
h.p.l.c. or 
fluorescence
TOTAL METABOLITES
2 X 1ml aliquotsI'
extract
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incubate 37°, 16h
ex trad
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buffer, pH 5.0 
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organic phase
h.p.l.c. or 
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FREE METABOLITES
organic phase
ih.p.l.c. or 
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GLUCURONIDES
I
extractI
organic phase
h.p.l.c. or 
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enzymes as used for biphenyl metabolism (Fig. 2.1).
2.2.16 Cumene Hydroperoxide-Supported Metabolism of Biphenyl
Cumene hydroperoxide in methanol (5pl) was added to tubes 
containing sodium potassium phosphate buffer (iml, O.IM, pH 7.6) 
and distilled water (0.3ml) giving a concentration range of 
0.01 to 5.0mM in the final incubation volume of 2ml. Thé 
reaction was started by addition of microsomal protein (4mg) 
and preincubated for 60s in a shaking water bath (37^, 120 
oscillations/min) before addition of biphenyl (0.5ml, 4mM in 
17o Tween 80). The incubation was continued for 5min then 
stopped by addition of HCl (0.5ml, 4M). Hydroxybipheiçrls 
were measured as previously described (sections 2.2.3.1, 2.2.3.2)
Preliminary experiments showed that a maximal rate of 
metabolism was achieved with a cumene hydroperoxide concentration 
of 0.2mM. This concentration was then used to investigate 
the effects of betamethasone and ANF (10 to 10 M) on 
cumene hydroperoxide supported biphenyl metabolism. Blanks 
and standards were prepared as previously described (section 
2.2.3).
2.2.17 Solubilised Microsomes
Rat liver micro somes were solubilised by the method of 
Lu and Levin (1972).
Washed liver microsomes, prepared as previously described 
(section 2.2.2) but resuspended to a protein concentration of 
30mg/ml, were diluted by addition of 7ml to glycerol (4.7ml), 
dithiothreitol (0.2ml, O.IM) and potassium phosphate buffer 
(9.5ml, O.IM, pH 7.7) containing sucrose (0.25M) and EDTA (lOmM). 
The mixture was sonicated for three 15s periods in a sonic 
bath then enough sodium cholate (10%) was added to give 
Img of cholate per mg of microsomal protein. The mixture
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was stirred at 4° for 20min then centrifuged (170 OOOg, 40min). 
The resulting clear supernatant was used in incubations with 
biphenyl and an NADPH generating system as previously described 
(section 2.2.3) /
Protein and cytochrome P-450 contents were determined 
before and after solubilisation.
2.2.18 Statistical Evaluation
Mean and standard error of the mean (S.E.M. ) have been 
stated where applicable. Statistical differences were 
determined by the paired students *t* test.
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CHAPTER THREE
ACTIVATION BY GLUCOCORTICOIDS
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3.1 INTRODUCTION
3.1.1 Glucocorticoids
Glucocorticoids are one of two groups of steroids synthesised 
in the adrenal cortex. They are characterised by a common 
parent structure, pregnane, with several functional groups.
For example:-
12 18
4 6
PREGNANE
CHgOH
0=0
HO
CORTISOL
Some of these substituents are essential for glucocorticoid 
activity, namely the llp-hydroxyl, the -3-keto moiety of 
ring A and the oi-ketol side chain at C-17. The ITx-hydroxyl 
is not obligatory but may facilitate glucocorticoid activity 
in certain species such as man. Many synthetic glucocorticoids 
have been developed with an extra double bond at A. and several 
other groups such as 9DC-fluoro, 2cxf-methyl, 6oc-methyl, 16o<- or p - 
methyl and 16o<-hydroxyl have been incorporated to enhance 
antiinflammatory activity and reduce the side effects of natural 
glucocorticoids.
Glucocorticoids have many functions and these have been 
reviewed extensively (Eisenstein, 1967; Rosen and Milholland, 
1971; Thompson and Lippman, 1974; Leung and Munck, 1975; Baxter 
and Rousseau, 1979). Briefly these actions include:
i) Antiinflammatory effects - suppression of local and general 
responses to infection.
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ii) Immunological effects - suppression of the allergic 
response and the formation of antibodies®
iii) Electrolyte effects - increased Na and water retention 
and increased K excretion.
iv) Carbohydrate and protein metabolism - regulation of protein 
and carbohydrate catabolism, release of glucose and increased 
resistance to insulin action. This includes specific effects
on the enzymes involved in protein catabolism. Enzymes which 
are induced by glucocorticoid treatment include tryptophan 
oxygenase (EC l.ll.lo4), tyrosine aminotransferase (EC 2.6.1.5), 
serine dehydratase (EC 4.2.1.13) and alanine aminotransferase 
(EC 2,6.1.2) (Rosen and Milholland, 1971).
Glucocorticoids are used in the treatment of collagen 
associated diseases such as rheumatoid arthritis, allergic 
diseases such as asthma and hay fever, blood disorders such as 
haemolytic anaemia, inflammatory eye diseases and dermatoses. 
Prolonged treatment may lead to adverse side effects including 
peptic ulceration, glaucoma, mental disturbances, hypertension 
and diabetes melitis.
Natural glucocorticoids may be metabolised by reduction 
at the C-3 and C-20 carbonyl groups and the ^  position in 
ring A, by oxidation of the llp-hydroxy group and by ring 
hydroxylation in several positions. Substitution of synthetic 
glucocorticoids in rings A, B and D results in hydroxylation 
becoming the predominant metabolic route.
3.1.2 Effects of Glucocorticoids on Drug Metabolism
Glucocorticoids are thought to be involved in the regulation 
of drug metabolising enzymes although the findings appear to 
be conflicting. Administration of glucocorticoids restores 
drug metabolising activity in adrenalectomised male rats to 
normal levels (Kato and Gillette, 1965; Castro ^  1970).
Bousquet ^  al (1965) demonstrated increased m  vivo metabolism
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of hexobarbital after injection of ACTH or corticosterone into 
rats and Stitzel and Fumer (1967) found increases in liver 
microsomal aniline 4-hydroxylase and ethylmorphine N-demethylase 
activities after subjecting rats to stress. However, rat 
liver aminopyrine N-demethylase was inhibited by corticosterone 
treatment (Radzialowski and Bousquet, 1968) and a similar effect 
on hexobarbital oxidation was observed after cortisol treatment 
(Fumer and Stitzel, 1968).
Some synthetic glucocorticoids have been shown to increase 
drug metabolising activity in liver (Somogyi ^  1971) and
extrahepatic tissues (Devereux and Fonts, 1975). Leakey and 
Fonts (1979) observed precocious development of liver cytochrome 
P-450 after administration of synthetic glucocorticoids to 
neonatal rats, whereas foetal and adult rats were less responsive. 
Tredger ^  ^  (1976b) observed increased rat liver metabolism 
of biphenyl, aniline, benzo(a)pyrene and ethylmorphine following 
administration of the more potent synthetic glucocorticoids 
whereas the natural glucocorticoids and their less potent 
synthetic analogues decreased or had no effect on these parameters 
These authors also reported a small increase in liver cytochrome 
P-450 content and NADPH-cytochrome c reductase following 
dexamethasone treatment and concluded that the inducing properties 
of synthetic glucocorticoids show some similarity to those of 
PCN or spironolactone. In contrast, Négrie ^  ^  (1979) reported 
that dexamethasone treatment caused increased liver weight 
but decreased liver cytochrome P-450 content.
Steroids are substrates of the same cytochrome P-450. 
dependent enzymes as xenobiotics (Kuntzman et 1964) and 
thus may be expected to inhibit xenobiotic metabolism vitro 
(see section 1.3). Indeed cortisol, progesterone, prednisolone, 
testosterone, aldosterone and oestradiol have all been shown 
to inhibit metabolism of some substrates (Tephly and Mannering, 
1968; Wada et al, 1968; Soyka and Long, 1972). However,
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Tredger ^  ^  (1975a) found no significant effect of any
glucocorticoid on addition to rat liver microsomal incubations,
on the 4-hydroxylation of biphenyl or aniline.
In contrast, biphenyl 2-hydroxylation was stimulated by 
both the natural glucocorticoid, corticosterone, and its 
synthetic analogues, prednisolone, dexamethasone and betamethasone 
Of these betamethasone caused the greatest increase in activity 
(Tredger ^  1976a). These effects may be related to the
novel observation of Breckenridge ^  ^  (1973) that infusion 
of hydrocortisone in man and dog caused an immediate shortening 
of the plasma half-life of antipyrine, possibly due to increased 
metabolism. It is therefore possible that regulation of drug 
metabolism by glucocorticoids may be mediated not only by 
enzyme induction but also by a more rapid activation process.
As discussed previously (section 1.6) the fluorescence 
assay used for measurement of 2 -hy dr oxybipheny 1 is unsatisfactory. 
It was therefore considered necessary to investigate the activatio 
of biphenyl 2-hydroxylation by glucocorticoids using the h.p.l.c. 
assay described previously (section 2.2.3.1).
The aims of this study were to investigate the effects 
of some natural and synthetic steroids on biphenyl hydroxylation 
and to attempt to correlate activation of biphenyl 2-hydroxyl- 
ation with glucocorticoid activity. The effects of the most 
potent activator, betamethasone, o-n some other drug metabolising 
enzymes have been investigated with particular attention to 
those enzymes susceptible to activation by other compounds.
In addition, induction of biphenyl hydroxylases and the effects 
of induction on activation have been examined.
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3.2 RESULTS
3.2.1 Effect of Steroids on Biphenyl Hydroxylation
The 22 vitro effects of some natural and synthetic 
glucocorticoids on biphenyl hydroxylation in liver microsomes 
from control male rats are shown in Table 3.2.1* Ihe gluco-. 
corticoids tested all caused activation of 2-hydroxylation 
with no significant effect (or slight inhibition) on 3- and 4- 
hydroxylation. Betamethasone consistently caused the greatest 
activation (430±24%). This figure represented a large variation 
in percentage activation in individual microsomal preparations 
showing increases from 2-7 fold,which appeared to be dependent 
upon the basal 2-hydroxylation activity and in fact represented 
a consistent increase of about 0* 6nmo 1/min/mg of microsomal 
protein. Betamethasone 17-valerate also caused a large 
activation. Corticosterone, dexamethasone, pregnenolone, 
cortisol and prednisolone caused smaller but significant 
activations.
Other steroids were also investigated for their activation 
effects (Table 3*2*2). Progesterone caused a large increase 
in 2-hydroxylation whereas the other sex hormones, oestradiol-17p 
and testosterone had no effect and norethynodrel and norethisteror 
both inhibited biphenyl hydroxylation. The inducing agent,
PCN was also found to activate 2-hydroxylation with no effect 
on 3- and 4-hydroxylation.
Betamethasone was found to cause increasing activation
at concentrations above 10 (Table 3.2.3)* Low solubility
-4prevented the use of higher concentrations than 10 M. Cortico­
sterone, dexamethasone and cortisol did not have any significant 
effect at concentrations of less than 10 ^M. Thus betamethasone 
was chosen as a model activator for future experiments.
The major route of biphenyl metabolism in control male
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Table 3.2.1 Effect of Glucocorticoids m  vitro on Biphenyl
Hydroxylation in Male Rat Liver Micro somes.
Steroid n Biphenyl Hydroxylation
(10“^M) 2-OH 3-OH 4-OH
Control 65 0.249±0.02^ 0.091+0.01 0.780+0.03
% Confrrol Activity
Betamethasone 65 430±24*** 101+3 101±2
Betamethasone-17- 
valerate
3 300+58** 97±8 91+11
Corticosterone 5 173+6""" 87±4 90+4
Dexamethasone 4 155+7"" 107+3 97+3
Pregnenolone 3 146+8" 82+11 96±8
Cortisol 5 135+8* 107+4 100+3
Prednisolone 4 134±7" 105±5 103±3
^ Control activities are expressed as nmol/min/mg of microsomal 
protein.
Results are means ± S.E.M. for n experiments.
Significantly different from control activity:
P<0.05; ""P<0.01; P<0.001
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Table 3.2.2 Effects of Non-glucocorticoidal Steroids in vitro
on Biphenyl Hydroxylation in Male Rat Liver
Microsomes.
Steroid n Biphenyl Hydroxylation 
% control activity
2-OH 3-OH 4-OH
Progesterone 5 237+17 113+4 114+13
Oestradiol-17 p 3 104±7 80+9 108±5
Testosterone 3 109+8 140±34 106+4
Ethynodiol
diacetate
3 129+4* 101±3 87±7
Norethynodrel 2 93 60 58
Ethisterone 2 103 97 96
Norethisterone 2 56 53 55
Pregnenolone-16*- 
carbonitrile
4
**
182+26 103+3 104+10
Results are means ± S.E.M. (where appropriate) for n experiments. 
Significantly different from control activity:
* P<0.05; ** P<0.01
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Table 3.2.3 Effects of Betamethasone on Biphenyl Hydroxylation
in Male Rat Liver Micro somes.
Biphenyl Hydroxylation
Betamethasone n % control activity
(M) 2-OH 3-OH 4-OH
IQ-S 4 101±5 91±5 97±5
10"^ 4 113±4 99±5 97+8
10-G 5 139+8* 97+5 101+9
10-5 5 214+35* 84+8 101+8
10-4 65 430124*** 101+3 101+2
Results are means ± S.E.M. for n experiments. 
Significantly different from control activity: 
P<0.05; P<0.001
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rat liver micro somes was 4-hydroxylation with 2- and 3-hydroxyl- 
ation as minor routes. Inclusion of betamethasone (10 ^M) in 
the incubation mixture increased the 2-hydroxylation above 
the 4-hydroxylation rate. This activation occurred in incubations 
as short as Imin (Fig 3.2.1). Control biphenyl hydroxylations 
were linear for up to lOmin whereas the betamethasone-activated 
2-hydroxylation was only linear for 5min. Thus routine 
incubations were performed for 5min only.
3.2.2 Effect of Betamethasone on other Drug Metabolising Enzymes
To ascertain whether this activation is unique to biphenyl
2-hydroxylation, the effect of betamethasone on the metabolism 
of other drug metabolising enzyme substrates was examined 
(Table 3.2.4). Aniline 4-hydroxylation, ethylmorphine N-déméthyl­
ation and 7- ethoxycoumarin 0-dééthylation were unaffected, 
whereas ethoxyresoruf in 0-dééthylation and glucuronyl transferase 
(with 4-nitrophenol as substrate) activities were inhibited by 
10-15% at the concentrations of betamethasone tested.
Benzo(a)pyrene hydroxylation as determined fluorimetrically 
(Dehnen et al, 1973) was subject to a small but significant 
activation (13%) when betamethasone (10 M) was included in 
the incubation mixture (Table 3.2.4). This was confirmed by 
repeating the incubations with ^H-benzo(a)pyrene and analysing 
the metabolites by h.p.l.c. and liquid scintillation counting.
In control incubations (no activator added) the major metabolites 
were phenols with elution times identical to authentic 3- 
and 9-hydroxybenzo(a)pyrene. Smaller amounts of 4,5-dihydro- 
dihydroxybenzo(a)pyrene and possibly 9,10-dihydrodihydroxy- 
benzo(a)pyrene were also detected (Fig, 3.2.2A). Incubation 
with betamethasone (10 ^M) caused a small increase (15%) only 
in the peak containing 3-hydroxybenzo(a)pyrene (Fig. 3.2.2B).
The remaining metabolic profile was unchanged. Incubation 
with ANF (10"^M) produced an identical metabolic profile to
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Fig, 3.2.1 Time Course of Biphenyl Hydroxylation in Control
Male Rat Liver Microsomes
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Table 3.2.4 Effects of Betamethasone vitro on Some Other
Parameters of Drug Metabolism in Male Rat Liver
Microsomes,
Betamethasone (M)
Enzyme activity n 10-7 10-6 10-5 10-4
Aniline 4-hydroxylase 3 100±5* 102±2 101±4 106+4
Benzo ( a)pyr ene 
hydroxylase ^
5 91±5. 113+2* 91±6 93+3
E thy Imorphine 
N-demethylase
2 - 102 106 103
7-Ethoxycoumarin 
0-deethylase
3 — 109±7 100+1 80+6
Ethoxyrès0 rufin 
0-deethylase
2 93 94 86 86
4-Nitrophenol- 
glucurony1trans feras e
2 ■- ■ — 90 81
Cytochrome P-450 3 - . — - 104+7
NADPH-cytochrome c 
reductase
3 -
/
- 106±4
Results are expressed as % control activity.
^ Benzo (a)pyrene hydroxylation was determined by the fluorescence 
method using 3-hydroxybenzo(a)pyrene as standard.
Results are means ± S.EoMo (where appropriate) for n experiments.
Significantly different from control, P < 0.05.
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betamethasone-activated benzo(a)pyrene metabolism* It should 
be noted that other minor hydroxy la ted metabolites, namely
1- and 7-hydroxybenzo(a)pyrene cochromatograph with 3-hydroxy­
benzo (a)pyrene (Selkirk 1976)*
Addition of betamethasone (10 ^M) had no effect on cytochrome 
P-450 levels or on NADPH-cytochrome c reductase activity 
(Table 3*2*4)*
3*2*3 Effects of other Activating Agents on Biphenyl Hydroxylatio
The effects of some other activating agents on biphenyl 
hydroxylation were also studied# Aniline 4-hydroxylation was 
maximally activated by 0*68M acetone, giving an increase of 
115%* The effects of acetone on biphenyl hydroxylation are 
shown in Fig* 3*2*3* An increase in 2-hydroxylation of about 
40% was found with acetone concentrations of 0*4-0*8M* Other 
concentrations had no effect* Biphenyl 3-hydroxylation was 
marginally increased (16%) by 0*34M acetone but inhibited 
above 0*68M* Biphenyl 4-hydroxylation was inhibited most 
strongly and was 40% of control activity at 1*0M acetone*
The non-ionic detergent, Brij 35 (0*1%) produced an increase 
of 245% in glucuronyltransferase activity towards 4-nitrophenol 
but had no effect on^ or marginally inhibited, biphenyl hydroxyl­
ation in the 2-, 3- and 4- positions (Table 3*2*5)*
ANF activated benzo(a)pyrene hydroxylation in control 
male rat liver micro somes and was shown to cause a concentration- 
related increase in biphenyl 2-hydroxylation but inhibited
4-hydroxylation at 0*5mM (Fig* 3*2*4)* ANF, or a metabolite, 
cochromatographed with 2-hydroxybiphenyl on the h*p*l*c. so 
the fluorescence assay was used to obtain these results* 
Consequently 3-hydroxybiphenyl was not determined* There 
was no fluorescence interference from ANF or its metabolites*
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Fig. 3.2.3 Effects of Acetone on Biphenyl Hydroxylation in
Male Rat Liver Microsomes
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Table 3.2.5 Effects of Brij 35 m  vitro on Biphenyl Hydroxylation
in Male Rat Liver Micro somes
Biphenyl Hydroxylation
Brij 35 (%) 2-OH 3-OH 4-OH
0.5 90±3^ 98±5 93+6
1.0 87±5 96+3 90+5
Results are expressed as % control activity. 
Results are means ± S.E.Mo for three experiments.
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Fig. 3.2.4 Effects of ANF on Biphenyl Hydroxylation in Male
Rat Liver Micro somes
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3.2.4 Induction of Biphenyl Hydroxylation
Liver microsomal biphenyl hydroxylation activities were 
measured after pretreating rats with the inducing agents 
phenobarbitone, 3MC and PCN (Table 3.2.6). Biphenyl 2-hydroxyl- 
ation was preferentially induced by 3MC whereas phenobarbitone 
had a greater effect on 3- and 4-hydroxylation. These effects 
were not completely selective as all activities were increased 
by both inducers. The steroid inducing agent, PCN, caused a 
small increase (29%) in biphenyl 2-hydroxylation and a decrease 
in 3- and 4-hydroxy lation*
Betamethasone appeared to have less effect on biphenyl 
2-hydroxylation in microsomes from pretreated rats than in 
microsomes from control rats (Table 3.2.7). The increase in 
2-hydroxylation caused by betamethasone (10 ^M) was 330% in 
control, 146% in corn oil control, 142% with phenobarbitone,
124% with PCN and a small but significant increase of 18% 
in liver microsomes from 3MC treated rats. It is interesting 
that these differences represent increases of 0.5-0.7nmol/min/mg 
of microsomal protein in each case (Table 3.2.8).
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Table 3,2.7 Effects of Betamethasone (10 ^M) vitro on
Biphenyl Hydroxylation in Liver Microsomes from 
Pretreated Male Rats.
Animal Biphenyl Hydroxylation
pretreatment n 2-OH 3-OH 4-OH
Control 5 430+24*** 101+3* 102+2
C o m  oil 5 246+12* 80+3 78+5
Phenobarbitone
(80mg/kg)
4 242+44* 92+2 106+11
3-Methyl cho lanthr ene 
(20mg/kg)
5 118+4" 95+3 99+3
Pregnenolone-16o(- 
carbonitrile 
(50mg/kg)
2 224 090 84
^ Results (means ± S.E.M., where applicable for n experiments) 
are expressed as a percentage of the activity in the absence of 
betamethasone.
Significantly different from control:
P<0.05; P <0.001.
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Table 3.2,8 Effects of Betamethasone (10 ^M) m  vitro on
Biphenyl Hydroxylation in Liver Microsomes from 
Pretreated Male Rats.
Animal
pretreatment
Change in Biphenyl Hydroxylation
2-OH 3-OH 4-OH
Control +617* -1 0
Corn oil +674 -24 -272
Phenobarbitone +675 -52 +124
3MC +516 -38 — 88
PCN +652 -5 -72
* Results are expressed as change in activity (pmol/min/mg of 
microsomal protein) from that found in the same microsomes 
in the absence of betamethasone.
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3.3 DISCUSSION
3.3.1 Structure-Activity Relationships
In agreement with the findings of Tredger ^  ^  (1976a) 
it has been shown that addition of betamethasone to mature male 
rat liver microsomes incubated with biphenyl, resulted in 
2-hydroxylation being increased but not 4-hydroxylation.
Several other steroids and ANF also caused a rapid increase in 
2-hydroxylation with no effect on either 3- or 4-hydroxylation.
There is no obvious structure-activity relationship for 
the activators (Fig. 3.3.1, Fig. 3.3.2). Betamethasone, a 
fluorine-substituted synthetic glucocorticoid consistently 
caused the greatest activation, possibly due to a slower metabolic 
deactivation than the natural steroids. Substitution of 
betamethasone at C-17 only slightly reduced the activating 
ability, but the stereo-isomer, dexamethasone, which generally 
has a similar biological activity to betamethasone, caused only 
a small increase in 2-hydroxylation.
Progesterone caused a large increase, whereas the other 
sex hormones, oestradiol and testosterone had no effect. It is 
notable that other monooxygénase reactions, for example 
£-nitroanisole déméthylation and aniline 4-hydroxylatipn, are 
inhibited by progesterone and other steroid hormones (Wada ^  al* 
1968; Soyka and Long, 1972; Soyka and Deckert, 1974). However, 
in addition to its other biological effects, progesterone also 
shows some glucocorticoid activity (Neumann, 1978). In an 
attempt to determine whether activation was related to gluco­
corticoid activity, it was decided to test a series of synthetic 
progestogens for their effect on biphenyl 2-hydroxylation. 
Progestogens are derivatives of either testosterone or hydroxy- 
progesterone, and only the latter group exhibit glucocorticoid 
activity (Neumann, 1978). Ethisterone, norethynodrel, 
19-norethisterone and ethynodiol diacetate are testosterone
— 69 —
Fig. 3.3.1 Structures of Some Good Activators of Biphenyl 
2-Hydroxylation
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Fie. 3.3.2 Structures of Some Weak Activators of Biphenyl 
2-Hydroxylation
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derivatives. The former two had no effect and 19-norethisterone 
inhibited biphenyl 2-hydroxylation (Fig. 3.3.3). However, 
ethynodiol diacetate caused a small activation. Unfortunately 
it was not possible to obtain any of the hydroxyprogesterone 
derivatives as their commercial production has been discontinued,
A direct relationship between glucocorticoid activity 
and activation has not been found. However, it appears that 
steroid activators, in common with glucocorticoids, possess 
the C-21 (pregnane) structure whereas C-19 steroids do not 
activate. Ethynodiol diacetate is the exception but the 
acetate substituent, at C-17 mimics the C-21 structure,. Other 
substituent groups on the steroid structure do not appear to 
be necessary.
The only non-steroid activator found was ANF. This is a 
planar molecule and bears virtually no resemblance to steroid 
structure (Fig. 3.3.1). Further experiments were indicated to 
determine whether ANF and the glucocorticoids activate biphenyl 
2-hydroxylation by a similar mechanism.
3.3.2 Activation by Betamethasone
The basal level of biphenyl 2-hydroxylation showed much 
interindividual variation whereas the 3- and 4-hydroxylation and 
the amount of betamethasone-activated 2-hydroxylation were 
more consistent. Thus the percentage activation showed very 
large deviations but the amount of activation varied much less.
Preincubation of the microsomes with betamethasone did 
not increase the degree of activation so it is unlikely that 
betamethasone requires metabolic activation to produce its 
effect. The activation occurred very rapidly, within Imin, 
with washed microsomes and therefore must involve a change 
in activity of preformed protein molecules.
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Fig. 3.3.3 Structures of Steroids that have no effect on, or 
inhibit Biphenyl 2-Hydroxylation.
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3.3.3 Effects of Betamethasone on other Drug Metabolising Enzymes
Ethylmorphine N-demethylase and 7 - ethoxycoumarin 0- deethylas e 
are, like biphenyl 4-hydroxylase, largely cytochrome P-450 
dependent. As expected they were unaffected by betamethasone. 
Benzo(a)pyrene hydroxylase and ethoxyresorufin 0-deethylase 
are both selectively induced by 3MC treatment and are therefore 
said to be cytochrome P-448 dependent, but only the former 
was activated by betamethasone. Thus activation of biphenyl 
2-hydroxylation does not reflect a change from cytochrome P-450 
to P-448 as previously suggested (Parke, 1977).
Aniline 4-hydroxylase was activated by acetone but not by 
betamethasone. Acetone also caused a small activation of 2- 
and 3- but not 4- hydroxylation of biphenyl. It is thus unlikely 
that betamethasone and acetone activate by similar mechanisms. 
Acetone does appear to be having a less specific effect on 
biphenyl hydroxylation possibly by a membrane effect. Glucuronyl- 
transferase is activated by membrane perturbrants but was 
slightly inhibited by betamethasone. Biphenyl hydroxylation 
was slightly inhibited by the detergent Brij 35. These results 
agree with those of Burke ^  ^  (1975) who found that biphenyl 
2- and 4-hydroxylation in hamster liver microsomes were inhibited 
by the detergent Tween 80. From our experimental results it 
would appear that betamethasone does not cause activation by 
membrane mediated effects and that activation of biphenyl ' 
2-hydroxylation is unrelated to activation of aniline 4-hydroxylas 
6r of glucuronyltransferase but may be similar to activation of 
benzo(a)pyrene hydroxylase by ANF. It is interesting that 
similar activation was observed when using both h.p.l.c. and 
fluorescence assays although neither is completely specific 
for 3,-hydroxybenzo(a)pyrene.
Betamethasone had no effect on NADPH-cytochrome c reductase 
under similar conditions to those causing activation of biphenyl 
2-hydroxylation and therefore probably acts directly on
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cytochrome P-450 and not on the reductase.
3.3.4 Induction of Biphenyl Hydroxylases
Pretreatment of rats with inducing agents resulted in less 
specific induction of biphenyl hydroxylases than has been 
reported elsewhere (Billings and McMahon, 1978). Biphenyl
2-hydroxylation was induced by all three inducers, with 3MC 
having the greatest effect and PCN only causing a slight 
elevation. Similarly, 3- and 4-hydroxylation were induced by 
both phenobarbitone and 3MC, although phenobarbitone did have 
à slightly greater effect. From this data it appears that 
biphenyl 2- and 4-hydroxylation are not particularly good 
markers for cytochrome P-448 and P-450 respectively as has been . 
suggested (Parke, 1977).
The results of activation by betamethasone in microsomes 
from pretreated rats could be analysed in two ways. If activation 
is expressed as percentages, it appears to be markedly reduced 
by phenobarbitone or PCN pretreatment and virtually abolished 
after 3MC pretreatment. However, the percentage activations 
are significant for each microsomal preparation. If the actual 
enzyme activities are examined the 18% increase observed in 
microsomes from 3MC treated rats is very similar to the 330% 
increase observed in control microsomes. This suggests that 
the activateable biphenyl 2-hydroxylase is not induced or. 
inhibited by treatment of rats with inducing agents.
In contrast to these results, both the percentage and 
quantitative activation of aniline 4-hydroxylation by acetone 
and 2,2'-bipyridyl are much reduced by 3MC induction (Powis 
and Boobis, 1975). Metyrapone, paraoxon and 1,10-phenanthroline 
inhibited aniline 4-hydroxylation and 2,2*-bipyridyl inhibited 
acetanilide hydroxylation in liver microsomes from 3MC treated 
rats (Anders, 1972; Powis and Boobis, 1975). Similarly, ANF 
inhibits benzo(a)pyrene hydroxylation in liver microsomes from
- 75
SMC treated rats but activates in liver microsomes from control 
and phenobarbitone treated rats (Wiebel ^  al, 1971).
3.3.5 Conclusion
These results suggest that glucocorticoids directly activate
either the control form of cytochrome P-450 or a form that is
inactive in control microsomes but is not affected by animal
pretreatment with enzyme inducers. The activation mechanism
of glucocorticoids appears to be different from that of various
agents on aromatic amine hydroxylation and glucuronyltransferase
but shows some similarity to activation of aryl hydrocarbon
hydroxylase. However, ^  vitro addition of glucocorticoids
does not appear to inhibit the cytochrome P-450 dependent drug
“4 _metabolising enzymes at concentrations up to 10 M, whereas ANF 
markedly inhibits the form(s) of cytochrome P-450 induced by 
pretreatment with 3MG.
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CHAPTER FOUR
AGE, SEX, SPECIES AND TISSUE 
DIFFERENCES IN ACTIVATION
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4.1 INTRODUCTION
4.1.1 Sex Differences
The duration and intensity of drug action is often greater 
in the adult female rat than in the adult male, and the subject 
has been reviewed extensively (Kato, 1974). Hoick ^  ^  (1937) 
observed that the duration of anaesthesia caused by the barbitu­
rates amobarbital, hexobarbital and pentobarbital but not 
barbital and phénobarbital, was considerably longer in female 
than in male rats. This sex-related difference was characteristic 
of adult rats only and castration of adult male rats lengthened 
the sleeping times to approximately those seen in females, 
suggesting the involvement of the male sex hormones (Hoick ^  al,. 
1937). Quinn et al (1958) demonstrated that the difference in 
sleeping time was due to a greater rate of metabolism" 
(deactivation) in male rats and that administration of testosterone 
to female rats increased the liver microsomal metabolism of 
pentobarbital. Conversely, administration of oestradiol to 
male rats inhibited the rate of metabolism.
Sex differences have been shown in metabolism of ethyl­
morphine, aminopyrine, benzo(a)pyrene and many other substrates 
(Kato and Gillette, 1965; Wiebel and Gelboin, 1975; Gurtoo and 
Parker, 1977; Nerland and Mannering, 1978). The magnitude of 
sex difference varies greatly with the substrate. Hexobarbital 
hydroxylation, aminopyrine N-déméthylation and pentobarbital 
oxidation are markedly sex dependent, aniline and zoxazolamine 
hydroxylation exhibit little or no sex difference whereas 
N-déméthylation of N-methylaniline and p-nitroanisole are 
intermediate (Kato and Gillette, 1965).
Sex dependent enzymes generally have the following 
characteristics:
1 ) enzyme activity is decreased by castration of male rats,
2 ) the decreased enzyme activity can be restored by testosterone
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treatment,
3) treatment of male rats with oestradiol decreases the 
enzyme activity,
4) treatment of female rats with testosterone increases the 
enzyme activity,
5) activity is significantly less in immature male and female 
and mature female rats than in mature male rats.
Although Kato and Gillette (1965) reported a lack of sex 
difference in the rate of aniline and zoxazolamine hydroxylations 
by rat liver microsomes. Pence and Schnell (1979) found that 
aniline hydroxylase activity in male rats was 30% greater than 
in females. This corresponded with the observed difference in 
microsomal cytochrome P-450 content and exhibited the other 
characteristics of a sex dependent enzyme. Similarly Gurtoo 
and Parker (1977) reported a sex difference in zoxazolamine 
metabolism. These discrepancies might be explained by differences 
in the strain of rat used.
Schenkman ^  ^  (1967b) observed that the affinity of liver 
microsomal cytochrome P-450 for substrates which form type I 
binding spectra (e.g. hexobarbital) was higher in male rats 
than in females but the spectral change of type II substrates 
(e.g. aniline) was similar. Hepatic cytochrome P-450 content, 
NADPH oxidase and NADPH-cytochrome P-450 reductase activities 
were about 35% higher in male than in female rats (Kato, 1974). 
These factors alone cannot explain, the large sex differences 
in metabolism of some substrates. There may also be differences 
in the populations of individual cytochromes P-450 present in 
male and female rat liver. Levin ^  ^  (1975) observed different 
proportions of short half-life (having a turnover of 7-8h) and 
long half-life (46-48h) species of cytochrome P-450 in adult 
but not immature male and female rats.
The phospholipid fraction of microsomes may also be 
involved in sex differences (Kato, 1974). Dénaturation of
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phospholipid in liver microsomes eliminated type I but enhanced 
type II spectral binding, suggesting that the type I binding 
site may be in a hydrophobic region of cytochrome P-450 or in 
the lipids of the microsomal membrane whereas the type II site 
is probably associated with the CO-binding site.
The actual mechanism of sex differences has not been 
elucidated but is generally agreed to be under androgenic control. 
Complete loss of sex difference can only be achieved by castration 
at birth. Gustafsson ^  ^  (1976) suggested this may be due 
to "neonatal imprinting" of testicular androgen in the pituitary 
stimulating development of androgen receptors. The presence 
of these receptors would account for the change in cytochrome 
P-450 population in the developing rat from rapid to slow turn­
over (Chung, 1977). In female rats, this change is thought to 
be inhibited by a "feminising factor" secreted by the hypothalamus 
in the absence of neonatal imprinting of androgens (Gustafsson 
and Stenberg, 1976; Skett, 1978).
No sex difference has been observed in the microsomes of 
lung, intestine and spleen but kidney microsomal activities 
of benzo (a)pyrene and zoxazolamine hydroxylation were found to 
be higher in female than in male rats (Chhabra and Fouts, 1974; 
Gurtoo and Parker, 1977).
In mouse liver microsomes, there is a sex difference in 
favour of females (Noordhoek ^  1978) but no sex differences
have been observed in either hepatic or extrahepatic microsomes 
from other species including rabbit, guinea-pig, cat, dog and 
man (Kato, 1974). Thus although study of sex differences in 
rat liver drug metabolising enzymes may increase our knowledge 
of these enzymes it may have little direct relevance to man.
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4.1.2 Temporal Changes in Monooxygenase Activity
Xenobiotic metabolism in neonates of various species, 
including rat, guinea-pig, rabbit and hamster, is very low.
The developmental patterns reported by different authors are 
often dissimilar even for the same species and substrate but 
there appear to be three distinct profiles (Short ^  1976):
a) a nearly linear increase from birth to a maximum at 30-40 
days (in rats),
b) a quiescent period of 15-20 days followed by a marked increase 
in activity,
c) rapid postnatal development with a maximum at 3-5 days 
followed by a decline to adult levels.
Examples of these patterns include a) biphenyl 4 -hydroxylase 
(Basu ^  al, 1971), b) ethylmorphine N-demethylase and 
c) aniline 4-hydroxylase (Gram ^  1969). It is notable
that enzyme activities exhibiting developmental patterns a) 
and b) also exhibit sex differences in mature rats. For 
example, liver microsomal ethylmorphine N-demethylase activity 
is similar in immature male and female rats but as maturity 
approaches activity decreases in females and increases in males 
while ethylmorphine 0 -deethylase activity is not sex dependent 
and follows pattern c), being slightly greater in immature 
rats than in adults (Nerland and Mannering, 1978). Wiebel 
arid Gelboin (1975) observed the development of a sex différence 
in rat liver benzo(a)pyrene hydroxylation at about 30 days 
and suggested this was due to the predominance of a different 
form of cytochrome P-450 in adult female rats to that in immature 
males and females and adult males.
Development of cytochrome P-450 and NADPH-cytochrome P-450 
reductase activity both follow pattern a) (Gillette and Stripp,
1975) and therefore cannot explain the different profiles of 
monooxygenase development. Evidence for the presence of a 
different population of cytochrome P-450 in immature rat liver
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was provided by Iba ^  al (1977) who observed that liver 
microsomes from neonatal rats exhibited a CO-binding spectrum 
maximum at 452nm (compared with 450nm in adults) and an 
equilibrium for the ethylisocyanide-induced absorbance peaks 
(427/455nm) at pH 7.9 (compared with pH 7.3 in adult males).
It is therefore possible that both developmental and sex 
differences in monooxygenase activity are due to the presence 
of different populations of cytochrome P-450.
Development of monooxygenase activity in most other 
laboratory animals resembles that in the rat (Neims ^  al,
1976). However, appreciable monooxygenase activity (20-40% 
of adult levels) has been found in midges tat ional human foetal 
liver. Cytochrome P-450 and NADPH-cytochrome P-450 reductase 
approached one third and one half of adult levels respectively 
indicating the human foetus has a much greater potential for 
activating (or deactivating) possible teratogens than animal 
models. This metabolising activity must also be subject to 
the same regulating factors as that of the mother.
4.1.3 Tissue Differences in Monooxygenase Activity
Although the liver is the primary site of xenobiotic 
metabolism, activity has been investigated in many extrahepatic 
tissues including kidney (Orrenius ^  1973), lung (Matsubara
et al, 1974), intestinal mucosa (Shirkey et al, 1979) and 
skin (Alvares ^  1973). Cytochrome P-450 content of
extrahepatic tissues is in the order: adrenal cortex > kidney
cortex > testis > small intestine and lung (Orrenius ^  1973).
Substrate specificity and susceptibility to inducers of 
mono oxygenase enzymes may vary disproportionately to the 
cytochrome P-450 content (Lake ^  1973). Different patterns
of induction may be partially explained by differences in the 
bioavailability of the inducing agent to different tissues but 
there may also be differences in the native cytochrome P-450
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populations.
4.1.4 Species Differences in Monooxygenase Activity
Rates of drug metabolism by liver microsomes show marked 
species differences not directly related to differences in the 
amounts of either NADPH-cytochrome P-450 reductase or cytochrome 
P-450 itself (Gillette, 1971). Tredger et ^  (1976a) noted 
differences in the effect of betamethasone on biphenyl 2 -hydroxyl­
ation in rat and hamster liver microsomes. A full study of 
species differences has not been attempted here, but a comparison 
of activation in rat, hamster and human liver has been made.
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4.2 RESULTS
4.2.1 Age and Sex Differences
In male rat liver microsomes biphenyl 2-, 3- and 4- 
hydroxylation activities increased from birth to peaks of 
0o68, 0.19 and l.OOnmol/min/mg of microsomal protein respectively 
at weaning (21days) (Fig. 4.2.1). Two and 3-hydroxylation then 
declined with age whereas 4-hydroxylation remained the same. 
Betamethasone-activated 2-hydroxylation increased to a peak 
of 1 .49nmol/min/mg of microsomal protein slightly after the 
basal activity at 28days (80-90g) before declining at the same 
rate as basal 2-hydroxylation. As a result, maximum activation 
was observed in liver microsomes from mature male rats.
In weanling female rats (Fig. 4.2.2) all enzyme activities 
were slightly lower than the male values but gave a similar 
degree of activation. Basal activities then declined with age 
at a greater rate than in male rat liver microsomes with a 
resultant increase in the sex difference. Betamethasone had 
a decreasing effect on biphenyl 2 -hydroxylation as the female 
rats matured until at 49days (200g) there was little or no 
activation.
Activation by corticosterone and progesterone was also 
studied in developing male and female rats and followed a 
similar pattern (Table 4.2.1).
The effects of betamethasone and ANF on liver microsomal 
benzo(a)pyrene hydroxylation were compared in mature male and 
immature and mature female rats (Table 4.2.2). The basal 
activities were greatest in immature rats and lowest in mature 
female rats. ANF exhibited a biphasic effect on benzo(a)pyrene
hydroxylation in liver microsomes from mature male rats causing 
activation at and 10 but inhibition at 10 ^M. However,
ANF had no effect or inhibited in liver microsomes from immature
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Fig. 4.2.1 Biphenyl Hydroxylation by Male Rat Liver Microsomes
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Fie* 4.2.2 Biphenyl Hydroxylation by Female Rat Liver Microsomes
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Table 4.2.1 Activation of Biphenyl 2-Hydroxylation by
Corticosterone and Progesterone in Developing
Male and Female Rat Liver Microsomes
Sex Age % Control Activity
(days) Progesterone Corticosterone
Male 1 0 317+10* 219+11*
15 253±21* 238+19*
2 1 191+17* 179+9*
28 225+21" 169+6"
35 315+23" 221+25"
49 290+18" 207+12"
Female 2 1 202±15* 175+13*
28
•JU
171+5" 157+11*
35 109+12 123+15
49 118+17 107+12
Corticosterone and progesterone (10 ^M) were added to 
microsomal incubations.
Results are means ± SoEoM. for three experiments. 
Significantly different from control, P < 0.05.
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Table 4.2,2 Sex Differences in Activation of Liver Microsomal 
Benzo(a)pyrene Hydroxylation
Activator Male Female
(M) 150-200g 45-55g 200-250g
0 0.85+0.07^ 1.09+0.40 0.58+0.11
% Control Activity
Betamethasone
10-7 91±5 ••
1 0 -G
‘V
113±2 112±4* 96+8
lo"^ 91±5 1 0 2 + 8 99+4
10-4 93±3 - -
ANF
10-7 102±3
1 0 -G
*
115±3 90±7 6 8 + 2**
ÿfÿf
1 0  ^ 110±3 93+6 65+8
10-4 - -
^ Control activities are expressed in nmol product formed/min/mg 
of microsomal protein.
Values are mean ± S.E.M. for three (female) or four (male) 
experiments.
Significant differences P<0.05, P< 0.01, P <  0,001,
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and mature female rats respectively (Table 4.2.2).
To investigate whether the lack of activation in liver 
microsomes from mature female rats was due to inhibition by 
oestrogen or a requirement for testosterone, oestradiol-17)3 
and testosterone were included in microsomal incubations with 
biphenyl and betamethasone. Alone, neither hormone had any 
effect on biphenyl hydroxylation (Table 4.2.3). In combination 
with betamethasone, both oestradiol and testosterone caused a 
small decrease in the degree of activation found with betametha­
sone alone. Similarly, addition of testosterone to mature 
female liver microsomes did not increase the activation by 
betamethasone. '
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Table 4.2.3 Effect of Sex Hormones on the Activation of
Biphenyl 2-Hydroxylation in Male Rat Liver
Microsomes
Steroid Biphenyl Hydroxylation
(1 0 ‘^M) 2-OH 3-OH 4-OH
Oes tradiol-17p 104±7* 80+9 108+5
Testosterone 109±8 140+34 106+4
Betamethasone 297+26* 91+14 108+11
Betamethasone + 
Oestradiol-17p
245±23*
*
79+9 111±4
Betamethasone + 
Testosterone
240+20*
a
86+7 114+6
Results are expressed as % of control activity. 
Results are means ± S.E.M, for three experiments. 
Significantly different from control, P< 0.05.
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4.2.2 Extrahepatic Metabolism
A comparison of biphenyl and benzo (a)pyrene hydroxylation 
activities in micro somes from small intestine, lung and kidney 
is shovm in Fig. 4.2.3. Biphenyl 4-hydroxylase activity was 
predominant in small intestinal and lung micro somes with very 
low benzo(a)pyrene hydroxylase. In contrast, benzo(a)pyrene 
hydroxylase was more active than biphenyl hydroxylases in kidney 
(and liver) micro somes. There was no significant sex difference 
in kidney microsomal metabolism of either biphenyl or benzo (a)- 
pyrene.
Betamethasone (10  ^to 10 ^M) had no effect on biphenyl 
or benzo(a)pyrene hydroxylase activities in small intestinal 
microsomes (Table 4.2.4). ANF caused a marked activation of 
benzo (a)pyrene hydroxylase in small intestinal micro somes 
(228% increase at 10 ^M ANF) and a smaller increase in biphenyl
2-hydroxylation (54% at 5x10 ^M ANF) with no change in 
4-hydroxylation.
Betamethasone had no effect and ANF either inhibited or 
had no effect on biphenyl or benzo (a)pyrene hydroxylation in 
rat lung microsomes (Table 4.2.5).
Benzo(a)pyrene hydroxylation in kidney cortex microsomes 
of both male and female rats was markedly inhibited at high 
concentrations of ANF (10 ^M and above) (Table 4.2.6). In 
contrast, betamethasone had no effect in male rat kidney 
microsomes and caused a small but consistent activation of 
benzo (a)pyrene hydroxylase in female rat kidney cortex micro somes,
There was also a sex difference in the effects of betametha­
sone on biphenyl hydroxylation in kidney cortex micro somes 
(Table 4.2.7). Betamethasone uniformly inhibited biphenyl 
hydroxylation in micro somes from male rats but either activated 
or had no effect in micro somes from female rats. The increase 
of 22% observed after incubation with 10 M betamethasone was
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not significant by the paired student *t* test due to the scatter 
of the individual results, but all did show activation to 
some extent. Additional animals need to be tested in order to 
achieve statistical significance.
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Table 4.2.4 Effects of Betamethasone and ANF on Hydroxylation 
of Biphenyl and Benzo (a)pyrene in Micro somes of 
Male Rat Small Intestine
Activator Benzo (a)pyrene Biphenyl Hydroxylation
(M) hydroxylase 2-OH 3-OH 4-OH
Betamethasone
1 0 -G 89±2^ 8 6 + 1 0 117+15 112±15
10-5 91±7 84+14 112±13 103±8
10-4 96±4 87+12 97±11 108+14
ANF
1 0 -G 112±9
10-5 228+25*
10-4 328±33*
—A
5x10 ^ 154+18* 105±4
Results are means ± SoEoM. for four experiments and are 
expressed as % of control activity.
Significantly different from control P<0.05o
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Table 4.2.5 Effects of Betamethasone and ANF on Hydroxylation
of Biphenyl and Benzo(a)pyrene in Male Ra^ Lung
Microsomes
Activator Benzo (a)pyrene Biphenyl Hydroxylation
(M) hydroxylase 2-OH 3-OH 4-OH
Betamethasone
IQ-t 101±5* 84 104 103
10-5 100±5 78 109 106
10-4 109+10 98±3 103+4 1 0 1 + 2
ANF
1 0 -b 110±17
10-5 95±6 ■
10-4
*
56+4 92 98
5x10-4 - 118+11
*
83+7
Results are means ± S.EoM. for four experiments or means 
of two similar experiments expressed as % of control activity.
Significantly different from control P < 0.05
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Table 4.2.6 Effects of Betamethasone and ANF on Benzo(a)pyrene
Hydroxylase in Male and Female Rat Kidney ^Cortex
Microsomes
Activator Benzo (a)pyrene Hydroxylas e
(M) Male Female
Betamethasone
10-5 1 0 0 + 2 103±6
10-5 98±4 108+6
10-4 101±3
*
115±3
ANF
10-5 90+8 98+10
10-5 38±2** 47±6**
10-4 30±2*** 33±2***
Micro somes were prepared from the combined kidney cortex of 
three rats for each experiment.
^ Results are means ± S.EoM. for four experiments expressed 
as % of control activity.
Significantly different from control:
P<0.05; P< 0.01; P < 0.001.
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Table 4.2.7 Effects of Betamethasone on Biphenyl Hydroxylation
in Male and Female Rat Kidney Cortex Microsomes
Sex Betamethasone Biphenyl Hydroxylation
(M) 2-OH 3-OH 4-OH
Male 10-5 74±7^ 8 8 ± 1 0 8 8 +2*
10-5 63+6*
-V
70+8 85+4*
10-4 80+5* 78+6 99+3*
Female 10-5 95±15 73+12 104+2
'■
10-5 122+9 1 0 2 + 6 106+12
10-4 105+7 87+10 99+1
Micro somes were prepared from the combined kidney cortex of 
three rats for each experiment.
^ Results are means ± SoEoM. for four experiments expressed 
as % of control activity.
Significantly different from control, P <0.05
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4.2.3 Hamster Liver Microsomal Biphenyl Hydroxylation
Biphenyl hydroxylation activities in hamster liver microsomes
are greater than in rat liver micro somes (Table 4.2.8).-^
Activities were 1.21, 0.36 and 2.03 nmol/min/mg of microsomal
protein compared with 0.25, 0.09 and 0.78 nmol/min/mg of
microsomal protein for 2-, 3- and 4-hydroxylation respectively.
The ratio of 3- to 4-hydroxylation is approximately the same
but 2-hydroxylation is proportionately much greater. Low
concentrations of betamethasone ( 1 0   ^to 1 0  ^M) inhibited
biphenyl hydroxylation in all three positions by up to 2 0 %.
A small but significant increase (23%) in 2-hydroxylation was 
-4found with 10 M betamethasone. Corticosterone and progesterone 
caused similar increases to those observed in rat liver microsomes.
4.2.4 Human Liver Microsomal Biphenyl Hydroxylation
Biphenyl 3- and 4-hydroxylation activities in the three 
preparations of male human liver micro somes were higher than 
in rat giving means cf 0.158 and 1.125 nmol/min/mg of microsomal 
protein respectively (Table 4.2.9). In contrast, biphenyl
2-hydroxylation activity was very low (mean 7 pmol/min/mg of 
microsomal protein). Addition of betamethasone (10 ^M) to the 
incubations again activated 2 -hydroxylation with no effect on
3- and 4-hydroxylation. The percentage activation varied from 
50% with subject T4 to 575% with subject T3. Although the 
trend in the results is clear cut, more data would be needed 
in order to obtain statistical significance. Similarly it 
would appear from the data that biphenyl hydroxylation activity 
in the single female human liver microsomal preparation studied 
is lower than in males. However, these values are similar to 
those of the least active male liver microsomal preparation 
(T7/3). The degree of activation of biphenyl 2-hydroxylation 
by betamethasone in female human liver micro somes (1 2 0 %) was 
within the range of male values, suggesting there is no sex
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Table 4.2.8 Effects of Glucocorticoids oii Male Hamster Liver
Microsomal Biphenyl Hydroxylation
Steroid cone Biphenyl Hydroxylation
(M) n 2-OH 3-OH 4-OH
Control - 7 1.21+0.17* 0.36+0.08 2.03+0.25
% Control Activity
Betamethasone 1 0 “ ^ 4 84±6 83+4 88±5
Betamethasone 1 0 “^ 4 88±5 80+4 89+4
Betamethasone 10“4 7 123±5** 90+2 97+4
Corticosterone 10“4 3 2 0 2 +1 2 * 103+9 109±9
Progesterone 10“4 4 276+49* 106+2 1 1 2 + 8
^ Control activities are expressed as nmol/min/mg of microsomal 
protein.
Results are means ± S.E.M. for n experiments.
Significantly different from control:
* P<0.05; P<0.01.
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Table 4.2.9 Effects of Betamethasone on Human Liver Microsomal
Bipheiyl Hydroxylation
Subj ect Sex Betamethasone Biphenyl Hydroxylation
(M) 2-OH 3-OH 4-OH
T3 M 0 8^ 205 1634
10-4 54 (675) 173 1314
T4 M 0 1 0 145 1237
10-4 15 (150) 146 1273
T7/3 M 0 4 123 503
10-4 12 (300) 1 2 0 485
T5/1 F 0 5 80 453
10-4 1 1  (2 2 0 ) 83 469
^ Results are expressed in pmol/min/mg of microsomal protein. 
Results are means of duplicate determinations of activities
in individual microsomal preparations.
Percentage activation is shown in parentheses.
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difference in activation in human liver micro somes.
Studies on activation in human liver micro somes were 
performed in collaboration with A.R. Boobis, G.C. Kahn and 
D.S. Davies (Royal Postgrad. Med. School, London) who have 
investigated activation of microsomal antipyrine metabolism 
(Table 4.2.10). Antipyrine 4-hydroxylation was activated by 
betamethasone in both rat and human liver microsomes whereas 
antipyrine 3-methyl hydroxylation was unaffected.
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Table 4.2.10 Effects of Betamethasone on Rat and Human Liver
Microsomal Antipyrine Hydroxylation
Species Betamethasone
(M)
Antipyrine Hydroxylation
3-Methyl-OH 4-OH
Rat 0 3.59±0.32* 1.59±0.18
10-4
b
93±4% 230+21%
Human 0 0.53+0.13 0.40±0.11
10-4 92+7% 164±16%
^ Control values are means ± S.E.M. (n=6 ) expressed in nmol/ 
min/mg of microsomal protein.
^ Betamethasone-activated values are percentage means ± S.E.M.
This data is reproduced by courtesy of A.R. Boobis, G.C. Kahn 
and D.S. Davies (Royal Postgrad. Med. School, London).
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4.3 DISCUSSION
4.3.1 Age and Sex Differences ^
The observed developmental profile of biphenyl hydroxylation 
in male rats agrees with the results of Basu ^  al (1971) with 
the exception that these authors reported a greater decrease in 
activity with age. Liver microsomal biphenyl hydroxylation 
activities were, in common with many other cytochrome P-450 
dependent hydroxylases, greater in male rats than in female 
rats. The relative proportions of the three hydroxylated 
products were found to be similar, in contrast to the results 
of Kahl ^  ^  (1977) who observed a much greater proportion of 
2 -hydroxylation in female rats.
Activation by betamethasone of both biphenyl 2-hydroxylation 
and benzo(a)pyrene hydroxylation exhibited similar marked sex 
differences; activation occurring in liver microsomes of mature 
male and immature but not mature female rats. All or nothing 
sex differences in drug metabolism of this type are very rare.
It is interesting that maximal activation of biphenyl 2-hydroxyl­
ation in male rat liver microsomes by both betamethasone and
/ -4
ANF was achieved at the limits of their solubilities (10 to 
10 M) whereas benzo (a)pyrene hydroxylation was maximally 
activated by concentrations of 1 0  and inhibited by concentra­
tions of 10 of each compound. The similarities suggest that 
activation of biphenyl 2- and benzo (a)pyrene 3-hydroxylation 
by glucocorticoids and by ANF may be by similar mechanisms. 
However, ANF had different effects to betamethasone on benzo (a)- 
pyrene hydroxylation in female rat liver microsomes suggesting 
the mechanisms are not identical. The differences and similaritie 
of these activations will be discussed further in Chapter J6 .
It appeared from vitro experiments that differences in 
oestradiol and testosterone levels were not directly responsible 
for the sex difference; indirect effects of the sex hormones
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I
1
could be studied by castration or oestradiol treatment of male
i
rats and by treating female rats with testosterone. j
I
j
These sex differences in activation being not merely, 
quantitative, suggest there may be qualitative differences 
in the enzymes concerned. Kahl et (1977) suggested that 
the cytochrome P-450 in control female rat liver microsomes 
exhibited characteristics intermediate between the forms found 
in liver microsomes of control and 3MC treated male rats. The 
data presented here provides further evidence for female rat 
liver cytochrome P-450 being different from that of control 
and 3MC treated male rats and of immature male and female rats 
as suggested by Wiebel and Gelboin (1975).
4.3.2 Activation in Extrahepatic Tissues
Biphenyl and benzo (a)pyrene hydroxylase activities in 
microsomes of extrahepatic tissue were lower than in liver 
microsomes, with different metabolic profiles produced in each 
tissue. Betamethasone did not appear to activate biphenyl 
2 -hydroxylation in any of the tissues studied and generally 
inhibited biphenyl hydroxylation in kidney microsomes from 
male rats. ANF however, caused a small activation of biphenyl 
2 -hydroxylation and a very marked increase in benzo (a)pyrene 
hydroxylation in intestinal microsomes. The latter result is 
in agreement with Stohs ^  ^  (1977) ^ o  observed a similar 
degree of activation by ANF of benzo (a)pyrene hydroxylation 
in isolated rat intestinal epithelial cells. It is of interest 
that the- degree of activation by ANF of the two enzyme activities 
in intestinal microsomes is the reverse of that found in liver 
microsomes.
In agreement with Wiebel ^  ^  (1971), benzo (a)pyrene 
hydroxylase in lung and kidney microsomes was more susceptible 
to inhibition by ANF than in liver microsomes. Similarly,
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betamethasone inhibited biphenyl hydroxylations in kidney 
microsomes of male rats whereas inhibition of biphenyl hydroxyl­
ation in liver microsomes has not been observed, under any 
circumstances.
As stated previously (section 4.1.1), sex differences in 
drug metabolism have not been observed in microsomes from lung 
or intestine but kidney microsomal activities of benzo(a)pyrene 
and zoxazolamine hydroxylation were higher in female rats 
than in males (Chhabra and Fouts, 1974; Gurtoo and Parker, 1977), 
It is interesting that although there was no significant 
difference between male and female rat kidney microsomes in 
control benzo(a)pyrene hydroxylase activities or in the response 
to ANF, betamethasone caused a small but significant increase 
in kidney microsomes from female rats only. Betamethasone may 
also have a slight activating effect on biphenyl 2 -hydroxylation 
in female rat kidney microsomes but inhibited in male. Thus 
there does appear to be a sex difference in favour of the 
female in kidney microsomes but it is not the complete reverse 
of that in liver microsomes.
It has been suggested that biphenyl and benzo(a)pyrene 
are metabolised by similar enzymes (Burke and Prough, 1976).
The tissue and sex differences in susceptibility of these 
enzymes to ANF and betamethasone emphasise that there are some 
similarities but many differences between them.
4.3.3 Species Differences
The basal biphenyl 2-hydroxylation activity in male 
hamster liver microsomes was much higher than in rat. Betameth­
asone ( 1 0  ^M) caused a small percentage activation representing 
an actual increase of approximately 0 .5nmol/min/mg of microsomal 
protein, closely resembling the observations in liver microsomes 
from male rats treated with 3MCo However, lower concentrations
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of betamethasone ( 1 0   ^to 1 0  ^M) inhibited biphenyl hydroxylation 
in all three positions equally. This biphasic effect could be 
explained by the involvement of two forms of biphenyl 2 -hydroxy­
lase, one with low Km and Vmax and high susceptibility to 
inhibition by betamethasone and one with high Km and Vmax and 
not susceptible to inhibition. Control activities would favour 
the former but when inhibited by higher concentrations of 
betamethasone, the latter would predominate, the observed 
activation being due to the enzyme with the higher Vmax.
Corticosterone and progesterone however caused similar 
percentage activations to those observed in microsomes from 
control rats suggesting these steroids may have differing 
actions from betamethasone in hamsters or that different 
receptors may be involved. These results are in contrast to 
those of Tredger et ^  (1976a) who found no activation by either 
betamethasone or corticosterone in hamster liver microsomes.
The profile of biphenyl hydroxylation in human liver 
microsomes was unexpected. Biphenyl 3- and 4-hydroxylation 
activities were, interestingly, greater than in rat liver 
microsomes, although in similar proportions. These results 
contradict the commonly accepted theory that rate of metabolism 
is inversely proportional to animal size (Walker, 1978). The 
amount of 2 -hydroxybiphenyl produced was very low and would 
have been undetectable, in the presence of such high concentra­
tions of 4-hydroxybiphenyl, by the fluorescence assay. Activation 
by betamethasone was much lower in liver microsomes from 
patient T4 than in the other preparations, whereas the basal 
2-hydroxylation activity was greater. It is of interest that 
patient T4 had been receiving methyl prednisolone treatment 
prior to death which may have contributed to these differences.
In agreement with Kato (1974) there was no apparent sex difference 
in monooxygenase activity in human liver microsomes.
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The data on activation in human liver suggests a similarity 
between the effects of betamethasone on biphenyl 2 -hydroxylation 
and antipyrine 4-hydroxylation, However, it should be noted 
that there was no relationship between the degree of activation 
of the two parameters in individual microsomal preparations.
For example, in sample T3, biphenyl 2-hydroxylation was subject 
to a large activation whereas antipyrine 4-hydroxylation was 
much less activated.
The wide individual variation in activation by betamethasone 
of biphenyl 2 -hydroxylation and antipyrine 4 -hydroxylation in 
human liver microsomes resembles that of the activation of 
benzo(a)pyrine, zoxazolamine and antipyrine hydroxylation by 
ANF in human liver microsomes reported by Kapitulnik ^  ^
(1977). These authors suggested the marked individuality for 
the activating and inhibiting effects of ANF was evidence for 
the presence of multiple forms of monooxygenases in varying 
amounts and proportions in the different samples and that ANF 
had a selective effect on certain of these enzymes.
An additional experiment which could be informative would 
be to compare the effects of cortisol and corticosterone in 
human liver microsomes. In the rat, corticosterone is the more 
important glucocorticoid and caused the greater activation.
In man, cortisol is more active and if the activating efficacies 
of the two steroids were reversed in human liver microsomes, it 
would be strong evidence for activation being a physiological 
function of glucocorticoids.
- 107 -
CHAPTER FIVE
MECHANISMS OF ACTIVATION
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5.1 INTRODUCTION
5.1.1 Relationship between in vitro and in vivo Metabolism
Most in vitro studies of drug metabolism are undertaken 
with tissue homogenates or subcellular fractions. These have 
the advantages of being simple to prepare, optimal assay 
conditions are easily established and the methods are readily 
adaptable from one species to another. However, it is widely 
recognised that such studies are of limited value in predicting 
both the rates of metabolism and rate-limiting steps in the 
metabolism of a drug vivo (Fry and Bridges, 1977).
The reaction rate within the whole cell may be affected 
by, for example, tissue-binding of the substrate, accèssability 
of cofactors and the presence of competing endogenous substrates. 
The activities of membrane-bound enzymes may be altered by 
disruption of the membrane during homogenisation. Also, release 
of compartmentalised endogenous factors during homogenisation 
may lead to activation or inhibition of the enzymes. The 
interdependence of phase I and phase II reactions can not be 
studied in subcellular fractions. Finally, the dependence of 
xenobiotic metabolism on the rate of entry of the compound 
into the cell and rate of excretion/secretion from the cell 
can not be assessed in subcellular preparations (Fry and Bridges 
(1977).
In order to determine whether enzyme activation in microsomes 
is rel event to the whole animal the effects of betamethasone 
in other models have been examined. The vitro alternatives 
to tissue homogenates and subcellular fractions include organ 
slices, isolated cells, tissue cultures and isolated perfused 
organs. Liver slices are subject to mechanical cell damage 
from the slicing procedure and metabolism is generally slow 
due to the difficulty with which substrates and nutrients diffuse 
into the interior of the slice (Bridges and Fry, 1976).
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Consequently, slices can produce irrepreducible results and 
are inferior to the other techniques available.
The advantages of using isolated cell suspensions have 
been reviewed by Fry and Bridges (1977). Briefly they possess 
the full complement of drug metabolising enzymes and cofactor 
levels and cellular transport mechanisms are probably preserved 
intact. Also, each cell is exposed to a similar concentration 
of drug, and obfuscating factors such as fluctuating hormone 
levels are avoided. Thus isolated hepatocytes are a useful 
tool for studying drug metabolism. Billings ^  al (1977) 
found that metabolism of some substrates was slower in isolated 
hepatocytes than in liver 9000g supematartor microsomes, but 
identical to that in perfused liver. Metabolism of drugs in 
isolated hepatocytes also correlated with m  vivo metabolism 
better than metabolism in liver 9000g supernatant or microsomes. 
Biphenyl 2- and 4-hydroxylation and subsequent conjugation 
reactions have been studied in isolated rat hepatocytes by 
Wiebkin (1976, 1978).
Isolated perfused livers are arguably closer as a model 
to the whole animal than are isolated hepatocytes and the 
technique does have some special merits. However, perfusions 
are technically difficult and also time-consuming, as only one 
variable can be measured with each liver. Thus the technique is 
not practicable for routine use. Biphenyl hydroxylation in 
perfused rat liver has been reported by Kahl ^  al (1978).
Activation of glucuronyltransferases is mainly observed 
in subcellular fractions (Dutton, 1977) but activation of 
monoox^^genases does occur in other metabolising systems.
Aniline 4-hydroxylation in isolated rât hepatocytes was activated 
by various agents, including ANF, p-nitroanisole, 7-ethoxycoumarin 
and, interestingly, biphenyl (Lowery and Bidlack, 1978).
Benzo (a)pyrene hydroxylation was activated by ANF in isolated
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rat hepatocytes (Vadi ^  1975) and by rotenone and ANF in
isolated rat intestinal epithelial cells (Stohs et al, 1977),
Acetone administration to rats m  vivo has been shown to 
cause increased aniline 4-hydroxylation vitro after very 
short time periods (30 to 60 min%.which was not inhibited by 
cycloheximide treatment and therefore did not involve induction 
(Clark and Powis, 1974). These authors suggested the mechanism 
was different from that of in vitro activation by acetone as 
the two effects were additive. In contrast, Kitada ^  al (1978) 
observed that increases in liver microsomal aniline 4 -hydroxyla­
tion and phenacetin 0 -dééthylation, 30min after treatment of 
rats with benzphetamine, acetone and me ty rap one, could be 
reversed by washing the microsomes and therefore involved a 
similar mechanism to vitro activation.
The aims of the present study therefore were to investigate 
whether activation of biphenyl 2 -hydroxylation occurs in isolated 
hepatocytes. In addition  ^ the effects of short term m  vivo 
administrât ion cf betamethasone to rats on m  vitro biphenyl 
2 -hydroxylation have been examined.
5.1.2 Mechanisms of Activation
The detailed mechanisms by which certain compounds activate 
the metabolism of other compounds is not known but several 
theories have been proposed. The .postulated mechanism for the 
ethylisocyanide stimulation of aniline 4-hydroxylation involves 
competition between ethylisocyanide and aniline for oxidised 
cytochrome P-450. The cytochrome P-450-isocyanide complex is 
reduced faster than the cytochrome P-450-aniline complex but 
following reduction aniline displaces the ethylisocyanide 
resulting in the hydroxylation reaction (Imai and Sato, 1968).
Me ty rap one is thought to change the equilibrium between two
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functionally different forms of cytochrome P-450. The decrease 
of one form appears as an * inhibition* of aminopyrine or 
hexobarbital metabolism, the concomittant increase of the other 
form results, in a * stimulation^ of other types of hydroxylation 
such as ring hydroxylation of acetanilide and aniline (Hildebrandt 
et al, 1969). This change in equilibrium could be achieved 
either by the formation of an inactive complex of me ty rap one and 
the first form of cytochrome P-450 resulting in a shift in 
electron flow to the second form which has little or no affinity 
for me ty rap one, or by interconversion of the two forms.
Anders (1968), on the basis of kinetic studies, speculated 
that the presence of two hydroxylases in liver microsomes could 
explain the effects of acetone. One hydroxylase may be character­
ised by a low Km and Vmax and a high sensitivity to inhibition 
by acetone. The second hydroxylase might possess both a high 
Km and Vmax and be relatively insensitive to inhibition by 
act one. In the presence of acetone, the former enzyme would be 
inhibited and the kinetic properties of the latter would result 
in the apparent enhancement. However, Powis ^  ^  (1977) 
observed a synergistic effect of NADH on aniline hydroxylation 
in the presence of acetone and suggested that acetone may 
facilitate the transfer of the second electron to cytochrome 
P-450 for oxygen activation, and that this step may be' rate- 
limiting in the 4-hydroxylation of aniline. More recently,
Anders and Gander (1979) demonstrated that acetone stimulated 
cumene hydroperoxide-supported microsomal aniline 4 -hydroxylation 
and concluded that as NADPH-cytochrome P-450 reductase and the 
transfer of the second electron cannot be involved (see Fig. 1.1), 
acetone probably exerts its effects by facilitating either 
formation of the activated oxygen species or the insertion of 
oxygen into the substrate.
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The mechanism by which 2,2'-bipyridine enhances aniline 
4-hydroxj'‘lation may be similar to that of acetone as the effects 
of the two compounds are additive at low acetone concentrations 
only (Anders, 1969). The mechanism by which paraoxon enhances 
aniline 4-hydroxylation is unknown but appears not to be related 
to that of acetone (Stevens ^  1972). Diethylmaleate and
the volatile anaesthetics are, however, thought to resemble acetone 
in their effects on aniline hydroxylation (Anders, 1978; Brown, 
1971). Polyamines may stimulate 2-hydroxylation of oestradiol 
by stabilising the microsomal membrane (Jellinck and Perry,
1967).
Activation of benzo(a)pyrene hydroxylation by ANF is 
thought to involve two enzymes; one sensitive to alcohol inhibi­
tion and ANF stimulation while the second form, predominant 
in extrahepatic tissues such as lung and skin, is less sensitive 
to alcohol inhibition but markedly inhibited by ANF (Wiebel 
et al, 1971)o This second form was thought to be increased by 
3MC treatment. The authors further suggested that ANF may 
cause an allosteric activation of the enzjnne complex, leading 
to an enhanced rate of electron flow to the enzyme..
In this study, the mechanism of activation of biphenyl
2 -hydroxylation has been investigated by enzyme kinetics and 
inhibition studies, by use of cumene hydroperoxide-supported 
metabolism and by solubilising microsomes.
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5.2 RESULTS
5.2.1 Activation in Isolated Rat Hepatocytes
Biphenyl metabolism has been studied in isolated hepatocytes 
from control male rats (60-80g) (Table 5.2.1). The relative 
proportions of total metabolites hydroxylated in the three 
different positions were similar to those found in control 
rat liver microsomes. Little or no unconjugated metabolites 
were detected. The predominant conjugates of 3- and 4-hydroxy- 
biphenyl were sulphates whereas equal proportions of sulphate 
and glucuronide were formed from 2-hydroxybiphenyl. There was 
very good correlation between the total metabolites as determined 
by acid hydrolysis and the total as determined by addition of 
unconjugated, glucuronides and sulphates in the cases of 3- and 
4-hydroxybiphenylo A major proportion (72%) of the further 
metabolites of 2 -hydroxybiphenyl was not hydrolysed by either 
'Ketodase* or sulphatase.
Preliminary experiments revealed that maximum activation of
biphenyl 2 -hydroxylation in isolated rat hepatocytes was 
-4produced by 10 M betamethasone without preincubation. The 
effects of this treatment on biphenyl metabolism are shown in 
Table 5.2.2. There were large increases in unconjugated
2 -hydroxybiphenyl and in 2 -hydroxybiphenyl glucuronide formation 
although the level of sulphate was unchanged. Acid hydrolysis 
showed an activation of 382% whereas the increase in the total 
of free, glucuronide and sulphate was only 174% suggesting that 
there was a greater increase in the formation of the unknown 
metabolite(s). Betamethasone inhibited biphenyl 3- and 4-hydroxy- 
lation with no difference in glucuronide and sulphate ratios.
ANF caused a marked inhibition of biphenyl 4-hydroxylation 
in isolated hepatocytes (Table 5.2.3) and had variable effects
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Table 5.2.1 Biphenyl Metabolism in Isolated Hepatocytes
Metabolite Biphenyl Hydroxylation
2-OH 3-OH 4-OH
Free
Glucuronide
Sulphate
Total
0 .0 1 *
0.88±0.25
1.18+0.57
2.07+0.44
<0 . 0 1
0.54+0.44
4.20±0.42
4.74±0.42
0.21±0.09
9.12+1.18
16.16±1.94
25.49+1.05
Total by acid 
hydrolysis
7,26+1.52 4.39+0.43 25.50+3.33
Biphenyl (70pM) was incubated with hepatocytes and the conjugates 
were hydrolysed by incubation with 'Ketodase* or sulphatase 
or total metabolites were determined by boiling with conc. HCl 
for Ih.
y
^ Results are expressed in nmol product formed/SOmin/10 cells 
and are means ± SoEeM. for 6 experimentso
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Table 5.2.2 Effect of Betamethasone (10 ^M) on Biphenyl
Metabolism in Isolated Rat Hepatocytes
Metabolite Biphenyl Hydroxylation
2-OH 3-OH 4-OH .
Free 1.90+0.85*** 0 . 0 1 0.11+0.05
Glucuronide 2.65+0.52* 0.27+0.10* 7.70+1.33
Sulphate 1.12+0.38 3.10+0.38 10.49+1.75
Total 5.67+1.03*
(274%)
3.37+0.50
(71%)
18.30+1.44**
(72%)
Total by acid 
hydrolysis
16.09+2.61
(482%)
3.88+1.12*
(8 8 %)
19.73+3.32* 
(77%) '
* Results are expressed as nmol product formed/30min/10^ cells 
and are means ± S.EoM. for 6 experiments.
Activation, expressed as % of control value (Table 5.2.1) is 
indicated in parentheses.
Significantly different from control:
* P<0.05; ** P<0.01.
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Table 5.2.3 Effect of ANF (2x10 ^M) on Biphenyl Metabolism
in Isolated Rat Hepatocytes
Metabolite Biphenyl Hydroxylation
2-OH 4-OH
Free
Glucuronide
Sulphate
Total
0 .0 1 *
1.52+0.44 
1.32+0.52 
2.83+0.77 (114%)
0.81+0.49
1.51+0.39*
**
3.94+1.58
6.26±1.35 (31%)***
Total by acid 
hydrolysis
6.88+1.47 (91%) 5.97+1.17 (24%)***
* Results are expressed as nmol product formed/30min/10 cells 
and are means ± SeE«M, for 6 experiments.
Activation, expressed as % of control value is indicated in 
parentheses.
Significantly different from control:
" PCO.05; ' PC 0.01; P< 0.001.
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on biphenyl 2 -hydroxylation. The means of six experiments were 
not significantly different from control values but hepatocytes 
from individual rats showed either activation or inhibition 
of 2 -hydroxylation with a more consistent inhibition of 
4 -hydroxylation, It should be noted that the control data 
is not shown but was very similar to those in Table 5.2.1
The fluorescent phenolic metabolites of benzo(a)pyrene 
formed approximately equal proportions of sulphate and 
glucuronide (Table 5.2.4). Betamethasone and ANF both increased 
the formation of total metabolites with ho selective effects.
_ g
Maximum activation was observed with 10 M ANF (119% increase) 
and lO" M betamethasone (135% increase). Higher concentrations 
of either compound did not inhibit metabolism contrary to 
observations in liver microsomes.
5.2.2 Activation in vivo
The effects of pretreatment of rats with betamethasone 
on the 2 2  vitro hydroxylation of biphenyl is shown in Table 
5.2.5. Increases of 35% and 55% were found in 2- and 3-hydroxy- 
lation respectively, in washed microsomes prepared 4h after 
pretreatment with a return to control activities at 6h after 
pretreatment. When postmitochondrial supernatant was used 
instead of microsomes a larger increase (65%) in 2-hydroxylation 
was apparent at 2h which was reduced to 35% at 4h and returned 
to control activity after 6h. There was then a second increase 
in activity (45%) at 24h after pretreatment. The changes in
3-hydroxylation were subject to greater variation and were 
not significant. There was no change in biphenyl 4-hydroxyl- 
ation at any time point in either washed micro somes or post- 
mitochondrial supernatant.
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Table 5.2.4 Effects of ANF and Betamethasone on Benzo(a)pyrene
Metabolism in Isolated Rat Hepatocytes
Activator Hydroxybenzo(a)pyrene Metabolites
(M) Free Glucuronide Sulphate Total
Control 0.12±0.03^ 0.24+0.08 0.3610.08 0.7210.09 ,
ANF,
lO-G 0.17+0.06 0.40±0.10 0.3210.09 0.8910.12 (124%)
10-5 0.39+0.09 0.7010.12 0.4910.19 1.5810.30*(219%)
10-4 0.33+0.10 0.46+0.13 0.2410.07* 1.0010-20 (139%)
Betgmethasone
0.22+0.07 0.78+0.05* 0.6810.11 1.69+0.09*(235%)
10-5 0.26±0.10 0.62+0.17 0.5410.12 1.4210.21*(197%)
10-4 0.25+0.08 0.40+0.11 0.6010 «14 1.2510.27*(174%)
* Results are expressed in nmol product formed/20min/2x10 cells 
and are means ± S.E.M. for three experiments.
Activation, expressed as % of control value, is indicated 
in parentheses.
Significantly different from control:
* P <0.05.
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Table 5.2.5 Effect of Pretreatment of Rats with Betamethasone
on in vitro Biphenyl Hydroxylation
Pretreatment Biphenyl Hydroxylation
time (h) n 2-OH 3-OH 4-OH
WashLed Micro sonles
2 4 114114^ 126+11 107+10
4 5
-k
138±8 155+17* 115+3
6 3 83±4 123+10 124+10
24 4 105±4 138+21 91+4
Postmitochondrial Siipematant
1 3 1 1 0 + 8 103+15 92+4
2 3 165±3** 119+18 107+6
4 3 135+10* 142+17 106+3
6 3 116+22 117+2 120+7
24 3 145+14* 140+22 118+14
Biphenyl hydroxylation was determined in either postmitochon- 
drial supernatant or washed micro somes of livers from rats 
pretreated with betamethasone (l4mg/kg, i.p.).
* Results are expressed as % of control value and are 
means ± SoEoM, for n experiments.
Significantly different from control:
/V VvVf
P<0.05, P<0.01.
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5.2.3 Kinetics and Inhibition Studies
The apparent Km and Vmax values of biphenyl 2-, 3- . 
and 4-hydroxylation were:
Km (mM) Vmax (nmol/min/mg of protein)
2-hydroxylation 0.27 0.15
3-hydroxylation 0 d 2  0.06
4-hydroxylation 0,65 1.05
Addition of betamethasone (10 ^M) to the incubations had no 
significant effect on these parameters for 3- and 4 -hydroxylation. 
The effects on 2-hydroxylation are shown in Fig. 5.2.1. The 
curved Lineweaver-Burk plot (l/v v. l/S) is consistent with 
a sigmoidal Michaelis-Menten plot (v v. S) and shows a small 
increase in Km aiid a much larger increase in Vmax. A plot 
of l/v against l/S is more useful than the Lineweaver-Burk plot 
for sigmoidal kinetics as it produces a straight line (Laidler 
and Bunting, 1973), By this method. Km and Vmax values of 
0.34mM and 1.05nmol/min/mg of microsomal protein were obtained 
for betamethasone-activated biphenyl 2 -hydroxylation,
Me ty rap one only exhibited a small inhibitory effect
on biphenyl 4 -hydroxylation in micro somes from male rat livers,
7% inhibition being observed at 10 ^M (Fig. 5.2.2). Biphenyl
2- and 3-hydroxylation were increasingly inhibited by me ty rap one
-5 -3concentrations of greater than 10 ^ M, At 10 M, the levels 
of inhibition were 57% and 6 8 % for 2- and 3-hydroxylation 
respectively. The betamethasone-activated 2-hydroxylation 
activity was inhibited more markedly and at a lower concentration 
(10 ^M). There was no apparent activation by betamethasone 
in the presence of 10 M me ty rap one (Fig, 5.2.3). In this 
experiment, betamethasone and me ty rap one were both added to 
the reaction mixture before preincubation. Alteration of the 
sequence by addition of either betamethasone or metyrapone after 
preincubation did not significantly alter the activation.
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Fig. 5.2.1 Lineweaver-Burk Plot of Biphenyl 2-Hydroxylation
in Male Rat Liver Microsomes
O)
1008 06 0- 4 0 4 02 0-20 0
1  (mM'^) 
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• control 2 -hydroxylation
-4,O 2-hydroxylation in the presence of betamethasone (10 M)
Each point represents the mean of two separate experiment 
with less than 1 0 % variation.
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Fig, 5.2.2 Effect of Metyrapone on Rat Liver Microsomal Biphenyl
Hydroxylation120 r
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Fie. 5.2.3 Inhibition by Metyrapone of Activation of Biphenyl 
2-Hydroxylation in Male Rat Liver Micro s ornes
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Values represent the percentage activation caused by 10 M
betamethasone (#---•) or 5x10 ^M ANF (■---■) in the presence
of each concentration of metyrapone.
Each point represents mean ± S.E.M. for three experiments.
- 124 -
Metyrapone had a similar effect on the activation of 
biphenyl 2-hydroxylation by ANF (Fig. 5.2.3). Metyrapone 
concentrations of 1 0  ^M and less had no effect on the activation 
whereas activation was completely abolished by concentrations 
greater than 1 0  ^M.
The combined effects of betamethasone and ANF are shown
in Fig. 5.2.4. As previously stated (section 3,2.3), ANF
activated biphenyl 2-hydroxylation. When added concommitantly
to incubations the total activation caused by betamethasone 
/ —4 \(10 M) and various concentrations of ANF was equal to that 
caused by betamethasone alone. Consequently, ANF appeared to 
inhibit the activation by betamethasone.
SKF 525A, in contrast to the differential effects of 
metyrapone and ANF, caused similar effects on betamethasone- 
activated biphenyl 2-hydroxylation and basal 2-, 3- and 4- 
hydroxylation (Table 5.2.6). Basal activities were inhibited 
by 20-25% by 10 ^M SKF 525A. The betamethasone-activated
2-hydroxylation was only marginally more affected (35% inhibition) 
Lower concentrations of SKF 525A (10 ^to 10 ^M) had no significant 
effect on any of the parameters measured.
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Fie. 5.2.4 Combined Effects of Betamethasone and ANF on Biphenyl
2-Hydroxylation in Male Rat Liver Microsomes
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■----- ■ Activation of biphenyl 2-hydroxylation by ANF (no
betamethasone).
e-----• Apparent activation by betamethasone (10”^M) in the
presence of ANF.
-4iTotal activation by ANF + betamethasone (10 M)
expressed as a percentage of the activity in the absence of 
either compound.
Each point represents mean ± S.E.M. for three experiments.
* Significantly different from control (no AN0, PC 0.05.
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Table 5.2.6 Inhibition of Biphenyl Hydroxylation by SKF 525A
in Rat Liver Microsomes
SKF525A n Biphenyl Hydroxylation
(M) BM2-0H® 2-OH 3-OH 4-OH
0 26 0.89+0.06^ 0.28±0.03 0.09+0.01 0.78±0.06
7o Control Activity
10-7 3 108±6 105+6 1 0 2 + 2 104+3
1 0 -G 3 1 1 1 ± 8 103+4 101+3 105+7
10-5 3 106+4 114+8 100+7 108+3
10-4 3 91+6 101+16 8 6 + 6 97+11
10-5 4 65+6**
*
79±4 74±8* 75+4*
BM2-0H represents biphenyl 2-hydroxylation in the presence 
of betamethasone ( 1 0  ^M)«
3L Results are means ± S.E.M. for n experiments.
Significantly different from control;
P <0.05, ' P< 0.01,
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5.2.4 Cumene Hydroperoxide-Supported Microsomal Biphenyl
Hydroxylation
Preliminary studies revealed that the optimal rate of 
biphenyl hydroxylation was achieved at 0.2mM cumene hydroperoxide 
(Fig. 5.2.5)o The relative proportions of hydroxybiphenyls 
produced were very different to NADPH-dependent metabolism with 
greater 2- and 3-hydroxylation activities and much reduced
4-hydroxylation.
The effects of including betamethasone in the cumene
hydroperoxide-supported microsomal reaction are shown in
Table 5*2.7. A maximum increase in 2-hydroxylation of 78%
was observed with 10 M betamethasone, compared with 330% with 
-410 M betamethasone for NADPH-supported metabolism. Biphenyl
3- and 4-hydroxylation activities were, as expected, unchanged 
in the presence of betamethasone.
Similarly, ANF caused a maximum activation of 53% at a
-7 -4
concentration of 10 M compared with 250% at 5x10 M ANF for
NADPH-supported metabolism (Table 5.2.8). ANF in concentrations 
-5of 10 M and greater inhibited both 2- and 4-hydroxylation.
Lower concentrations of ANF had no effect on 4-hydroxy lat ion*
5.2.5 Activation in Solubilised Micro somes
Rat liver micro somes were solubilised in sodium cholate 
(img/mg of protein) resulting in 48% loss of cytochrome P-450 
content (per mg of protein). Biphenyl hydroxylation in 
in solubilised micro somes and the effects of betamethasone 
are shown in Table 5.2.9. Biphenyl 4-hydroxylation showed 
similar activity to that in intact micro somes on a per nmol of 
cytochrome P-450 basis, whereas 2- and 3-hydroxylation were 
reduced. Betamethasone caused a concentration-related activation 
of biphenyl 2 -hydroxylation that was also less than in intact 
microsomes. It was notable that the 2- and 3-hydroxylase 
activities were subject to considerable variation between
- 128 —
different solubilised preparations whereas 4-hydroxylation 
was much more consistent.
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Fig. 5.2.5 C-umene Hydroperoxide-Supported Biphenyl Hydroxylation
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Each point represents the mean of two similar experiments.
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Table 5.2.7 Effects of Betamethasone on Cumene Hydroperoxide-
Supported Microsomal Biphenyl Hydroxylation
Betamethasone Biphenyl Hydroxylation
(M) 2-OH 3-OH 4-OH
0 0.69±0.12* 0.21±0.03 0.26±0.03
% Control Activity
10-9 104±6 99+4 93±3
IQ-S 109+7 92±b 92±8
1 0 -^ 118+9 89+5 96+2
- 6 *
1 0 178+15 120+13 118±23
10-5 127+31 101+23 95+18
10-4
.
109+34 97+22 92+27
^ Control activities are expressed in nmol/min/mg of microsomal 
protein.
All values are means ± S.E.M. for three experiments. •
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Table 5.2.8 Effects of ANF on Cumene Hydroperoxide-Supported
Microsomal Bipheiyl Hydroxylation
ANF Biphenyl Hydroxylation
(M) 2-OH 4-OH
0 0.54+0.13* 0.38+0.01
% Control Activity
10-9 108+6 115+6
lo"^ 113+1** 105+3
10-7 153+?* 113±6
1 0 -G 134+7* 102±4
10-5 49+5** 86+7
10-4 23+3** 72±2**
Control activities are expressed in nmol/min/mg of microsomal 
protein.
All values are means ± S.E.M. for three experiments. 
Significantly different from control:
P<0.05, P <0.01.
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Table 5.2.9 Effect of Betamethasone on Biphenyl Hydroxylation
in Solubilised Rat Liver Microsomes
Betamethasone Biphenyl Hydroxylation
(M) 2-OH 3-OH 4-OH
0 55±11* , 24+4 392+4
% Control Activity
1 0 "® 121+15 96±5 103+3
10-7 119±11 98±9 1 0 2 ± 2
- 6
1 0 119±8 94+8 1 0 0 ± 1
10-5 144+9* 107+11 105+3
10-4 260±24*• 104+11 98±2
^ Control activities are expressed in pmol/min/mg of microsomal 
protein.
All values are means ± S.E.M. for three experiments. 
Significantly different from control, P < 0.05.
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5.3 DISCUSSION
5.3.1 Activation in Hepatocytes and in vivo
The relative proportions of 2-, 3- and 4-hydroxybiphenyl 
produced in isolated rat hepatocytes were very similar to those 
formed in rat liver micro somes. As previously reported by 
Wiebkin et al (1978% 3- and 4-hydroxybiphenyl were predominantly 
conjugated with sulphate with the remainder as glucuronide. The 
majority of 2 -hydroxybiphenyl formed an unknown conjugate that 
was hydrolysed by boiling with HCl (approx. 5M) for Ih but not 
by incubation with * Ketodase* or sulphatase. A discrepancy 
in recovery of 2 -hydroxybiphenyl after incubation with isolated 
hepatocytes and deconjugation was previously noted, but not 
explained, by Wiebkin ^  al (1976). This deficit could be 
explained if 2 -hydroxybiphenyl glucuronide was partially 
resistant to hydrolysis by 'Ketodase* which is produced for 
hydrolysis of conjugated steroids. Alternatively a conjugate 
other than glucuronide or sulphate may have been produced. 
Methoxy derivatives of 3- and A-hydroxjrbiphenyl have been 
identified (Halpaap ^  1978) but 2-methoxybiphenyl has not
been reported to date. Glutathione conjugates of biphenyl 
would be unlikely to hydrolyse to give 2 -hydroxybiphenyl 
exclusively. Similarly the 2,3-dihydrodiol, if produced, would 
break down to form both 2- and 3-hydroxybiphenyl. A phosphate 
conjugate is also possible but again these have not been 
reported as metabolites of biphenyl in the literature. This 
result clearly warrants further investigation.
Betamethasone caused activation of biphenyl 2-hydroxylation 
in isolated hepatocytes of a similar magnitude and at the same 
concentration as in liver micro somes. It is interesting that 
formation of free 2 -hydroxybiphenyl, its glucuronide and the 
unknown metabolite were all increased whereas formation of 
2 -hydroxybiphenyl sulphate was unchanged in the presence of
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betamethasone. Wiebkin ^  ^  (1978) observed that at low 
concentrations of 2- and 4-hydroxybiphenyl, sulphate conjugation 
was predominant and with increasing concentration, glucuronida- 
tion became more important. These authors suggested this was 
due to the limited availability of sulphate within the cells.
In betamethasone-activated hepatocytes there is more 2-hydroxy­
biphenyl produced but it seems unlikely that this is sufficient 
to render the sulphate levels limiting.
Biphenyl 3- and 4-hydroxylation in isolated rat hepatocytes 
were inhibited by betamethasone. This result was une^gected 
as these activities were not affected by betamethasone in rat 
liver micro somes. The only other example of inhibition by 
betamethasone was in male rat kidney cortex micro somes where 
biphenyl 2-, 3- and 4-hydroxylation were all inhibited equally.
A possible explanation for the inhibition in hepatocytes is 
that betamethasone itself, or a metabolite is being conjugated 
and therefore competing for the same enzymes. Betamethasone 
did not have a direct effect on the hepatocytes as the viability 
of either contol or betamethasone-treated hepatocytes did not 
change during the course of the incubations.
The effects of ANF on biphenyl hydroxylation in isolated 
hepatocytes were more complex. In the individual experiments 
performed, 2-hydroxylation was either activated or inhibited 
by 2x10 M ANF, with the result that the mean was not significant­
ly different from the control value. Biphenyl 4-hydrox^rlation 
was markedly inhibited by ANF in contrast to the observations 
in liver micro somes, where inhibition was only 10% at 5x10 
ANF. It therefore appears that the cytochrome P-450 in isolated 
rat hepatocytes is more susceptible to inhibition by ANF than 
in liver micro somes and that this inhibition in certain, as yet 
undefined, conditions masks the activating effects of ANF.
In contrast, benzo(a)pyrene hydroxylation in isolated 
hepatocytes was much less susceptible to inhibition by ANF than
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in liver microsomes from rats of the same age. Thus 10 M ANF
caused an activation of 119% and 10 ANF did not inhibit. In
liver microsomes, a maximum activation of 15% was obtained in
—  0
the presence of 10 M ANF and higher concentrations caused 
increasing inhibition. Betamethasone also caused a much greater 
activation of benzo (a)pyrene hydroxylation in isolated rat 
hepatocytes than in liver microsomes. Neither activating agent 
had a specific effect on formation of sulphates or glucuronides 
but caused a general increase in total metabolite production.
Isolated hepatocytes are thought to bear .more relationship 
to the whole animal than subcellular fractions. But whereas 
betamethasone treatment of hepatocytes and liver microsomes 
caused a similar activation of biphenyl 2-hydroxylation, 
betamethasone pretreatment of rats caused only a small increase 
after 2 to 4h. These differences may be due to betamethasone 
being poorly absorbed from the peritoneal cavity. This could be 
investigated by administering betamethasone intravenously if 
a suitable vehicle could be found. Betamethasone has a very 
low solubility in water and is sold commercially in ointments; 
more soluble derivatives are used for injections.
Tredger et ^  (1976a) reported an increase in liver 
microsomal biphenyl 2-hydroxylation of 340%, 4h after intra- • 
peritoneal administration of betamethasone to rats. These 
workers used unwashed microsomes whereas the present data was 
obtained with washed microsomes. -It is notable that enhancement 
of aniline 4-hydroxylation following pretreatment of rats with 
benzphetamine In vivo is found in 9000g supernatant but not 
in washed microsomes (Kitada ^  1978). When biphenyl
2-hydrox)rlation was determined in liver postmitochondrial 
supernatant after pretreatment of rats with betamethasone, 
the observed activation was greater but not as large as 
reported by Tredger ^  sN. (1976a). This discrepancy cannot 
be explained but it appears that at least some of the activation
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observed after animal pre treatment may be due to betamethasone 
bound to cytochrome P-450 and that this complex may be disrupted 
during isolation of the microsomes. To avoid this biphenyl 
hydroxy lat ion could be measured in isolated hepatocytes 
prepared from rats pretreated with betamethasone.
In contrast to the findings m  vitro. an increase in liver 
microsomal biphenyl 3-hydroxylation was also observed after in 
vivo pretreatment with betamethasone. This increase was apparent 
in washed liver microsomes but not in postmitochondrial supematani 
The variation in 3-hydroxylation activity in pretreated rats 
was greater than in control rats and in the absence of activation 
of 3-hydrox))"lation in microsomes or in hepatocytes, this may not 
be a true activation.
5.3.2 Kinetics and Inhibition Studies
The curved Lineweaver-Burk plot produced by betamethasone- 
activated biphenyl 2-hydroxylation could be explained by either 
an allosteric mechanism or by the involvement of two biphenyl 
2-hydroxylases. The control plot (without betamethasone) was 
a straight line suggesting that if two enzymes are producing 
the curved plot the second enzyme must be completely latent 
or have very similar properties to the first in the absence of 
betamethasone. On the other hand, if betamethasone causes 
activation by binding to an allosteric site of a single enzyme, 
an increase in the apparent Km would not be expected as this 
reflects a change in the active site of the enzyme. The system 
is probably more complex and the most likely explanation seems 
to be that betamethasone allosterically activates one of two 
or more biphenyl 2-hydroxylases.
Metyrapone had only a small effect on biphenyl 4-hydroxyla­
tion, contrary to previous reports (Burke and Trough, 1976), 
but inhibited 2- and 3-hydroxylation more markedly. The
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similarity between inhibition of 2- and 3-hydroxylation was 
unexpected as 3-hydroxylation resembles 4-hydroxylation in its 
induction characteristics and also in its lack of sensitivity 
to glucocorticoids. It has been suggested that conversion of 
cytochrome P-450 to the form induced by 3MC may be responsible 
for the activation of biphenyl 2-hydroxylation (Parke, 1977). 
However, activation was completely inhibited by addition of 
metyrapone with betamethasone before incubation, suggesting 
that a species of cytochrome P-450, highly sensitive to metyrapone 
is involved. This could be an enzyme that normally metabolises 
steroids as metyrapone is a most potent inhibitor of adrenal 
steroid hydroxylation (Leibman, 1969). Metyrapone appears to 
inhibit the activated enzyme rather than inhibiting the activation 
process as it had similar effects when added to the incubation 
before, after or concomittantly with betamethasone.
As betamethasone-activated bipheiyl 2-hydroxylation activity 
was more sensitive to metyrapone inhibition than the basal enzyme 
activity, this provides further evidence for the involvement 
of two enzymes in the activation.
Metyrapone had a similar inhibitory effect on activation 
by ANF suggesting that betamethasone and ANF have similar effects, 
Also, the activation effects of betamethasone and ANF were not 
additive above a maximum value. ANF is a potent inhibitor of 
liver microsomal drug metabolising enzymes from animals pretreated 
with 3MC but has less effect on.control and phenobarbitone 
pretreated animals (Wiebel ^  1971). If enhancement of
biphenyl 2-hydroxylation reflected a change from control to 
3MC type of cytochrome P-450, Aî'TF would be expected to inhibit 
the activated enzyme.
SKF 525A, another inhibitor of cytochrome P-450 related 
enzymes from liver of control and phenobarbitone treated rats, 
(Anders, 1971) was less effective than metyrapone as an inhibitor 
of biphenyl 2- and 3-hydroxylation. It had a similar effect on
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hydroxylation activity in all three positions with only slightly 
greater inhibition of betamethasone-activated 2-hydroxylation.
5.3.3 Mechanistic Studies
Betamethasone and ANF caused much smaller maximal activation 
of cumene hydroperoxide-supported biphenyl 2-hydroxylation than 
of the NADPH-supported reaction. These activations were seen 
with 10 y and 10 ^M ANF and. betamethasone and were similar to 
the activations of NADPH-supported 2-hydroxylation at these 
concentrations. At higher concentrations, activation was reduced 
and ANF caused marked inhibition. These results suggest that 
cumenehydroperoxide-supported biphenyl 2-hydroxylation activity 
responds to betamethasone and ANF in a similar fashion to the 
NADPH-supported reaction when the activators are present in 
low concentrations. At higher concentrations, the reaction is 
more sensitive to inhibition by these compounds. This could be 
explained again by a multiple enzyme system where activation of 
one enzyme is masked by the greater inhibition of another.
These experiments lead to a similar conclusion to that of 
Anders and Gander (1979); i.e. that activation does not involve 
an electron transport system. Evidence for this has previously 
been provided by the lack of any effect of betamethasone on 
NADPH-cytochrome c reductase (section 3.2.2). However, 
cumene hydroperoxide-supported biphenyl metabolism showed a 
profile very different from that found with NADPH, making 
interpretation of results difficult and further experiments 
of this type would probably be of limited value. These difference! 
agree with Capdevila et ^  (1980) who suggested that the 
reaction mechanisms operative in the presence of organic . 
hydroperoxide differs in several regards from that functional 
in the presence of NADPH.
Interpretation of the results with solubilised microsomes 
is also difficult due to the many obfuscating factors involved.
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Cholate was chosen for the solubilisation as it causes minimal 
conversion of cytochrome P-450 to P-420 and inhibition of 
hydroxylation reactions is slight, even at relatively high 
concentrations (Lu and Levin, 1974). Thus the specific activity 
of biphenyl 4-hydroxy las e (per nmol, of cytochrome P-450) was 
very similar to that in intact micro some s. The decreased 
activities of 2- and 3-hydroxylation and the decreased percentage 
activation by betamethasone could be due to selective destruction 
or inhibition of the enzymes involved. The purpose of solubilisa­
tion was to disrupt the microsomal membranes. This was achieved 
as evidenced by the absence of microsomal pellet after 
centrifugation of the solubilised preparation (170 OOOg, 40min). 
That betamethasone activated biphenyl 2-hydroxylation in the 
disrupted system is further evidence that the activation is 
not a membrane effect but is mediated by cytochrome P-450 
directly.
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CHAPTER SIX
FINAL DISCUSSION
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The metabolism of chemicals leads to the formation of both 
biologically inert and highly reactive products. For this 
reason there is now considerable interest in the regulation of 
cytochrome P-450 dependent mono oxygénas es and the balance between 
synthesis of non-toxic and toxic metabolites. According to 
Wiebel (1980), chemicals may alter monooxygenase activity by at 
least three mechanisms. They may:
1) trigger a series of intracellular regulatory and biosynthetic 
steps that lead to an increase or decrease of enzymic activity,
2) directly interfere with the catalytic process, or
3) cause the inactivation or destruction of the cytochrome.
Of these, mechanism 1) and in particular, induction, is considered 
to be the most important and consequently has been most extensive­
ly investigated.
Although inhibition is considered to be the major example 
of mechanism 2), this category also includes activation, an 
important regulatory mechanism in intermediary metabolism but 
often omitted in reviews on the regulation of drug metabolism. 
Early studies on glucuronyltransferase activation, while 
providing evidence for enzyme compartmentalisation (Winsnes,
1959) barely considered the physiological relevence. Activation 
and inhibition studies have also been used as evidence for 
the multiplicity of cytochrome P-450 (Anders, 1968; Wiebel and 
Gelboin, 1975). The data presented in this thesis suggests 
that activation of certain monooxygenases may be more important 
than previously considered. To this end, certain questions 
must be answered:
Maximum activation was observed at concentrations of activators 
much greater than would occur in vivo. How can this be relevant?
Biphenyl 2-hydroxylation was maximally activated at the
solubility limits of betamethasone and ANF. This was in
—3incubations containing 10 M biphenyl and 2mg of microsomal
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protein per ml. The optimal concentration of the activating
agent appeared to be dependent on the concentration of both
the substrate and the enzyme in microsomes. In support of
-6
this view, an optimal concentration of 10 M betamethasone or
ANF caused maximal activation of benzo(a)pyrene hydroxylation
-4
in microsomal incubations containing 10 M substrate and 0.3mg 
of microsomal protein per ml. However, biphenyl hydroxylation 
would be undetectable by present methods if very low concentra­
tions of biphenyl were used, so this theory is difficult to 
prove*
What is the relationship between betamethasone and ANF?
All the chemicals found to cause activation of biphenyl 
2-hydroxylation have structures similar to glucocorticoids 
except for ANF, which has no apparent structural similarity.
But there are many similarities in the activation effects of 
betamethasone and ANF. Both compounds caused similar percentage 
activations of both biphenyl 2-hydroxylation and benzo(a)pyrene 
hydroxylation in rat liver microsomes. The effects on biphenyl 
2-hydroxylation were not additive above the maximum activation 
caused by betamethasone and showed a similar pattern of 
inhibition by metyrapone. The activation of benzo (a)pyrene 
hydroxylation appeared to be selective for the C-3 position 
with both compounds o
These similarities suggest that betamethasone and ANF have 
identical activation mechanisms, but there are some differences. 
ANF is a potent inhibitor of microsomal enzymes from 3MC 
pretreated rats and inhibits some activities in liver microsomes 
from untreated rats whereas betamethasone had no inhibitory 
effects in control rat liver microsomes. Thus ANF and betameth­
asone at 10 activated benzo(a)pyrene hydroxylation, but at 
higher concentrations betamethasone had no effect and ANF 
inhibited. Similarly the sex difference in activation by the
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two compounds was not identical. Betamethasone activated 
biphenyl 2-hydroxylation and benzo (a)pyrene hydroxylation in 
male and immature female rats and had no effect in adult female 
rats. ANF activated benzo(a)pyrene hydroxylation in male rats, 
had no effect in immature female rats and inhibited in liver 
microsomes from mature female rats. This could be explained 
by ANF having different effects on two enzymes ; one being 
activated by both betamethasone and ANF and present in liver 
of male and immature female rats, the other being inhibited 
by ANF but not betamethasone and present in liver of immature 
and mature female rats. The combined effects could produce 
the observed lack of effect in immature female rats.
A similar mechanism would explain the difference in 
activation in rat lung microsomes where ANF inhibited and 
betamethasone had no effect, and in kidney cortex microsomes 
where betamethasone activated benzo(a)pyrene hydroxylase in 
the female and had no effect in the male and ANF inhibited 
more markedly in the male than in the female.
The only difference in activation that could not be 
explained by the mechanism proposed above is that observed 
in small intestinal microsomes. ANF caused marked activation 
of benzo(a)pyrene hydroxylation and a small activation of 
biphenyl 2-hydroxylation whereas betamethasone had no effect 
on either reaction.
Which dirug metabolising enzymes can be activated by these 
compounds?
Biphenyl 3- and 4-hydroxylation, aniline 4-hydroxylation, 
ethylmorphine N-déméthylation, 7 - ethoxycoumarin and ethoxy- 
resorufin 0-dééthylation, antipyrine 3-methyl hydroxylation 
and UDF-glucuronyl transferase were all unchanged by addition 
of betamethasone to microsomal incubations. It appears that 
there is no similarity between activation of biphenyl
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2-hydroxylation by betamethasone and activation of aniline 
4-hydroxylase by acetone or of UDP-glucuronyltransferase by 
detergent. ^
The only enzyme activities studied that were activated 
by betamethasone were biphenyl 2-hydroxylation, antipyrine 
4-hydroxylation and apparently, 3-hydroxylation only of 
benzo(a)pyrene. For each substrate, hydroxylation at one 
position only is activated. Zoxazolamine hydroxylation has 
not been investigated with betamethasone but work by Kapitulnik 
et al (1977) has shown that ANF has a similar effect 
effect on the rates of hydroxylation of zoxazolamine, benzo (a)- 
pyrene and antipyrine.
The question then arises - is there one or more activateable 
enzymes?
The structures of these substrates are shown beloWj with 
the activation-susceptible hydroxylation positions arrowed.
/
Biphenyl
CH
CH
000
Benzo (a)pyrene
Antipyrine Zoxazolamine
The above diagram reveals that for each substrate it is 
an ortho-hydroxylation that can be activated, so a single 
enzyme may be responsible. Alternatively betamethasone and 
ANF may activate a group of closely related enzymes.
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ANF also stimulates metabolic activation of aflatoxin B1 
to aflatoxin-2,3-oxide in human but not in rat liver microsomes 
(Buening 1978) and metabolism of benzo(a)pyrene to
b-hydroxymethylbenzo(a)pyrene (Sloane, 1975). As neither of 
these involves o-hydroxylation, different enzymes may be 
involved.
What is the significance of the sex and tissue differences in 
activation?
Sex differences of drug metabolism are normally quantitative 
with greater activity in male rats than in females (Kato, 1974). 
The absence of activation in female rat liver microsomes 
cannot be explained by quantitative differences in enzyme 
activity. There is a sex difference in glucocorticoid receptor 
concentration in rat liver (Endres et al, 1979) but these are 
located in the soluble fraction of the cell not the endoplasmic 
reticulum so this is not likely to be a contributing factor.
The activateable enzyme may be absent from adult female rat 
liver but if it is there in immature animals why should it 
be lost with age in the female only? Another possibility is 
that in adult female rat liver the predominant bipheity’l 
2-hydroxylase is sensitive to inhibition by betamethasone which 
masks the activation effects as appears to happen with ANF.
The inhibitory effects of betamethasone are unclear. 
Inhibition was not observed in male rat liver microsomes but 
biphenyl 3- and 4-hydroxylation were inhibited in isolated 
rat hepatocytes. Biphenyl 2-, 3- and 4-hydroxylation were all 
inhibited by betamethasone in male rat kidney cortex microsomes.
The reversal of the sex difference in rat kidney cortex 
microsomes is interesting but again difficult to explain. It 
cannot be significant to the whole animal as vivo 
investigations of sex differences reflect liver microsomal 
enzyme activities (Kato, 1974) but may have some relevence
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within the kidney. Thus sex and tissue differences in activation 
provide further evidence for the multiplicity of these 
cytochrome P-450 dependent hydroxylases. In common with 
many other sex differences in drug metabolism, the difference 
in activation was not observed in human liver microsomes so 
is not directly related to man.
What is the activation mechanism?
Activation occurs rapidly m  vitro without preincubation 
and therefore involves increased activity of preformed enzyme 
molecules, unlike induction which involves ^  novo protein 
synthesis. There are basically three ways in which activation 
could occur:
T) a membrane effect increasing substrate/cofactor availability 
to the enzyme,
2) stimulation of the reductases associated with cytochrome 
P-450, thereby increasing the electron flow to the cytochrome,
3) a direct effect on cytochrome P-450 itself at one or more 
of the possible points of interaction (Fig. 6.1).
We have shown that biphenyl 2-hydroxylation is not 
activated by detergents and that betamethasone does not activate 
UDP-glucuronyltransferase which is located deep in the endoplasmic 
reticulum. Betamethasone did activate biphenyl 2-hydroxylation 
in a solubilised microsomal system which does not contain 
intact, membranes. These points indicate that the mechanism is 
not likely to involve a membrane effect.
If betamethasone stimulated the cytochrome P-450 associated 
reductase the activation would probably not be selective for 
hydroxylation of this limited number of substrates in one 
position only. In support of this, betamethasone had no effect 
in vitro on NADPH-cytochrome c reductase but did activate cumene 
hydroperoxide-supported biphenyl 2-hydroxylation which eliminates 
the two reductase steps in the cytochrome P-450 cycle (Fig. 6.1).
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Fie. 6.1 Proposed scheme for the mechanism of catalysis by 
cytochrome P-450 (Nebert and Jensen, 1979).
R-OH R -H
P-450 (Fe)
(6) (1)
(R -H )P -450 (F e -0 )^ +
HOH
(5) (2)
HOOH
(R-H) P -4 5 0  (Fe-HOOH)^^ H) P -450(Fe)
(4) (3)
2H (R-H) P -450  (Fe-^2*
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Kinetic studies suggested the involvement of more than one 
enzyme and/or an allosteric mechanism. Inhibition data and the 
sex and tissue differences in activation by ANF and betamethasone
provided further evidence for more than one enzyme. In hamster
• • “ 4
liver microsomes, 10 M betamethasone caused activation of
biphenyl 2-hydroxylation but lower concentrations inhibited.
This biphasic effect is similar to that observed by Kapitulnik 
^  (1977) for activation of zoxazolamine and antipyrine 
hydroxylation by ANF. These authors suggested the involvement 
of more than one enzyme system, with some being inhibited by 10 
ANF and others being activated by higher concentrations of ANF. 
Betamethasone produced the same pattern of inhibition and 
activation of antipyrine 4-hydroxylation in human liver 
microsomes (G.Co Kahn, personal communication).
The most likely explanation is therefore direct stimulation 
of one or more cytochrome P-450 dependent hydroxylases. There 
is evidence that the activation may be caused by the glucocort­
icoid (or ANF) binding to an allosteric site of the enzyme.
The possible points of interaction can be seen in Fig. 6.1. 
Activation is probably not caused by increased binding of 
biphenyl to cytochrome P-450 (step 1) in the presence of 
betamethasone (Tredger, 1973). Since cumene hydroperoxide- 
supported biphenyl 2-hydroxylation was activated by betamethasone 
steps 2 to 4 are probably not involved. The most plausible 
suggestion is therefore that activation occurs during oxygen 
insertion into the substrate (step b).
In order to obtain fuller understanding of the activation 
mechanism, the activateable enzyme must be purified. Lu and 
West (1972) found that ANF activated benzo (a) pyrene hydroxylation 
in a reconstituted cytochrome P-450 system purified from 
phenobarbitone pretreated rat liver but inhibited in a 
reconstituted system from 3MC pretreated rats. These studies 
were repeated using the same reductase and lipid fractions
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and varying the haemoprotein. The results indicated that the 
observed differential effects were due to the haemoprotein, not 
the reductase or lipid (Lu and West, 1972),
The activateable enzyme is different from the forms of 
cytochrome P-450 that can be induced by phenobarbitone, 3MG 
or PCN as the quantitative activation (expressed as nmol/min/mg 
of microsomal protein, not percentage) was the same in liver 
microsomes from control and pretreated rats. It is highly 
sensitive to inhibition by metyrapone but not ANF. It cannot, 
therefore, be cytochrome P-448 dependent as has been suggested 
(Parke, 1977).
What is the significance of the activation?
The consequences of activation are difficult to investigate 
in vivo. Wiebel (1980) reviewed the effects of flavones on 
tumorigenesis of a number of carcinogenic polycyclic hydrocarbons. 
The incidence of skin tumours was decreased following simultaneous 
application or pretreatment with ANF. These effects may be 
attributed to either inhibition of the enzymes causing metabolic- 
activation of the carcinogens, or to induction of the enzymes 
causing detoxication of the reactive metabolites. Glucocorticoids 
also inhibit tumour promotion but this is thought to be due 
to their antiinflammatory activity rather than any effect on 
drug metabolising enzymes. Betamethasone is a weak inducer 
of monooxygenases with specificity similar to that of PCN 
(Tredger, 1973). These other effects are all difficult to 
separate from activation when studying the whole animal.
Dexamethasone has been used to stabilise cytochrome 
P-450 dependent enzyme activities in cultured foetal hepatocytes 
(Jo Eo Gielen, personnel communication). In the presence 
of dexamethasone, benzo(a)pyrene hydroxylase is slightly 
activated by ANF and markedly inhibited by metyrapone. If 
dexamethasone is removed from the culture medium there is ai
- 150 -
immediate return to mono oxygenase activity similar to that 
induced by 3MC (inhibited by ANF and insensitive to metyrapone). 
The mechanism of this effect of dexamethasone is wriknovTn but 
may be related to the activation of hydroxylases by glucocorti­
coids observed in liver microsomes and isolated hepatocytes.
Activation of biphenyl 2-hydroxylation has been shown not 
only in liver microsomes and in isolated hepatocytes but also 
in vivo, 2h after intraperitoneal administration of betamethasone 
to rats. Infusion of hydrocortisone into human subjects also 
caused an immediate decrease in the half-life of antipyrine 
(Breckenridge et al, 1973). Activation must, therefore have 
some physiological relevence.
Glucocorticoids play an important role in regulation of 
enzymes of both intermediary and xenobiotic metabolism. This 
function is thought to be mediated by stimulation of the synthesis 
of new enzyme molecules, i.e. induction, a process which involves 
a delay of several hours (Conney, 1967). This may be adequate 
for xenobiotic metabolism but a more immediate activation of 
preformed enzyme molecules must be necessary for some enzymes 
of intermediary metabolism. Also it is most unlikely that we 
should have an allosteric regulatory enzyme merely for o-hydroxyl- 
ation of biphenyl, benzo(a)pyrene, antipyrine and zoxazolamine. 
There must be an endogenous substrate for the activateable 
enzyme(s). It is possible that the activation is caused when 
glucocorticoid levels are elevated following stress situations 
or excitement. If so, the endogenous substrate may be a 
precursor of a metabolite that is required, or a reactive 
metabolite that must be detoxified and excreted.
What is the endogenous substrate of the activateable enzyme(s)?
The answer to this question is, unfortunately not known 
Possibilities include steroids (even glucocorticoids themselves), 
or prostaglandins. Laurie acid (w-l)- or 11-hydroxylation is
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activated by ANF in human liver microsomes (Okita et al, 1979) 
These authors suggested the natural substrate of the cytochrome 
P-450 mediated (w-l)-fatty acid hydroxylase system could be a 
prostaglandin. However, if the activateable enzyme preferentially 
catalyses o-hydroxylation, steroids are more plausible substrates.
In conclusion, it seems that this question is the most 
important. If this can be answered then we will know how 
important the activation is and what the explanations are to the 
other unanswered questions.
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